PD-l1 antibody drug conjugates
PD-L1-binding antibodies and antibody-drug conjugates with specific CDR sequences and drug payloads address the limitations of current cancer therapies by enhancing tumor targeting and growth inhibition, improving treatment efficacy and tolerability.
Patent Information
- Application Number
- PCT/US2026/027065
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current therapies targeting PD-L1 for cancer treatment face challenges such as non-responders, resistance, and immune-related adverse events, necessitating improved cancer therapies.
Development of PD-L1-binding antibodies and antibody-drug conjugates with specific CDR sequences and linker-drug moieties to enhance tumor targeting and inhibit tumor growth, utilizing antibodies with extended half-life and various drug payloads like maytansinoid, auristatin, and topoisomerase inhibitors.
The conjugates exhibit improved affinity, internalization kinetics, ADC cytotoxicity, tolerability, and efficacy, offering enhanced cancer treatment options with reduced side effects.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000003_0002 
Figure IMGF000004_0001
Abstract
Description
Attorney Docket No.: C1818.70005WO00PD-L1 ANTIBODY DRUG CONJUGATESRELATED APPLICATIONSThis application claims the benefit under 35 U. S. C. § 119(e) of U. S. Provisional Application No. 63 / 802,095, filed May 8, 2025, the entire content of which is hereby incorporated by reference.REFERENCE TO AN ELECTRONIC SEQUENCE LISTINGThe content of the electronic sequence listing (C181870005WO00-SEQ-CRP.xml; Size: 171,045 bytes; and Date of Creation: May 6, 2026) is herein incorporated by reference in its entirety.BACKGROUND
[0001] PD-L1 (Programmed Death Ligand 1) is a protein expressed by some cancer cells. PD-L1 can help cancer cells evade detection by the immune system by binding to PD-1 on immune cells (such as T cells) and preventing such immune cells from attacking the cancer cells. Overexpression of PD-L1 on cancer cells can lead to immune evasion, tumor growth, and poor clinical outcomes in some cancers.
[0002] PD-L1 has become a target for therapies to treat cancers. However, current therapies based on targeting PD-L1 suffer from drawbacks, such as non-responders, resistance, and immune-related adverse events. There remains a need for improved cancer therapies.SUMMARY
[0003] The present disclosure addresses this need with improved PD-L1 -binding antibodies and antibody fragments, as well as antibody-drug conjugates that target PD-L1.
[0004] In one aspect, provided are PD-L1 -binding antibodies or antigen-binding fragments thereof comprising (a) an immunoglobulin heavy chain variable domain (VH) comprising complementarity-determining (CDR) regions CDR-H1, CDR-H2, and CDR-H3 and (b) an immunoglobulin light chain variable region (VL) comprising CDRs CDR-L1, CDR-L2, and CDR-L3, wherein (i) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 118, 119, and 120, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 121, DAS, and SEQ ID NO: 122, respectively; (ii) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 123, 124, and 125, respectively, and the CDR-L1, CDR-L2, and CDR-L3Attorney Docket No.: C1818.70005WO00comprise the amino acid sequences SEQ ID NO: 126, 127, and 128, respectively; or (iii) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 129, 130, and 131, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences SEQ ID NO: 132, DAS, and SEQ ID NO: 133, respectively.
[0005] In some embodiments, the VH comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 134 and the VL comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 135.
[0006] In some embodiments, the PD-L1 -binding antibody or antigen-binding fragment further comprises an Fc polypeptide. In some embodiments, the Fc polypeptide is an IgG polypeptide. In some embodiments, the IgG polypeptide is selected from the group consisting of IgGl, IgG2, IgG3, and IgG4.
[0007] In some embodiments, the Fc polypeptide comprises a means for extending the halflife of the antibody or antigen-binding fragment. For example, the half-life extending means may comprise a mutation or set of mutations in the Fc polypeptide. In some embodiments, the set of mutations is selected from the group consisting of M252Y / S254T / T256E (YTE), M428L / N434S (LS), M428L / N434A (LA), H433K / N434F (KF), and L309D / Q311H / N434S (DHS).
[0008] In one aspect, provided are antibody-drug conjugates represented by Ab-Lp-Dq; wherein Ab comprises a PD-L1 -binding antibody or antigen-binding fragment thereof as disclosed herein, L is a linker, D is a drug moiety, p is 1 to 10, and q is 1 to 10. In some embodiments, p and q are equal. For example, p and q may be between 2 and 8, e.g., 2, 4, 6, or 8. In some embodiments, p and q are 4. In some embodiments, p and q are 8. For example, q may be between 2 and 8, e.g., 2, 4, 6, or 8. In some embodiments, q is 4. In some embodiments, q is 8. For example, p may be between 2 and 8, e.g., 2, 4, 6, or 8. In some embodiments, p is 4. In some embodiments, p is 8.
[0009] In some embodiments, D is a drug moiety selected from the group consisting of: maytansinoid, auristatin, anthracycline, calicheamicin, tubulysin, duocarmycin, a topoisomerase inhibitor, a radioisotope, liposome comprising a toxic payload, protein toxin, taxane, indilino-benzodiazepine pseudodimer, and pyrrolobenzodiazepine.
[0010] In some embodiments, D is represented by:Attorney Docket No.: C1818.70005WO00[Formula 1].
[0011] In some embodiments, L is represented by the following formula:-L1-L2-Lp-NH-(CH2)n1-Ld-,whereinn1represents an integer of 0 to 6,L1represents -(Succinimid-3-yl-N)-(CH2)n2-C(=O)- wherein n2represents an integer of 2 to 8,L2represents -NH-(CH2-CH2-O)n5-CH2-CH2-C(=O) or a single bond, wherein n5represents an integer of 1 to 6,Lprepresents a GGFG (SEQ ID NO: 143) tetrapeptide,-NH- (CH2)n1-Ld- is selected from the group consisting of -NH-(CH2)3-C(=O)-, -NH-CH2-O-CH2-C(=O)-, and -NH-(CH2)2-O-CH2-C(=O)-, and-(Succinimid-3-yl-N)- has a structure represented by:[Formula 2],Attorney Docket No.: C1818.70005WO00
[0012] In some embodiments, the Lp-Dqcomprises an L-D having a structure represented[Formula 3].
[0013] In another aspect, disclosed herein are antibody-drug conjugates comprising the Formula:wherein Ab is a PD-L1 -binding antibody or antigen-binding fragment thereof comprising:Attorney Docket No.: C1818.70005WO00a heavy chain having the amino acid sequence of SEQ ID NO: 138, anda light chain having the amino acid sequence of SEQ ID NO: 139; andwherein g represents an average drug antibody ratio (DAR); andg is 8.
[0014] In some embodiments, D has a structure represented by:[Formula 4]
[0015] In some embodiments, the Lp-Dqcomprises an L-D having a structure represented by:[Formula 5].
[0016] In some embodiments, the Lp-Dqis arrived at by reacting a structure represented by:Attorney Docket No.: C1818.70005WO00[Formula 5A],
[0017] In some embodiments, provided are antibody conjugates comprising a PD-L1-binding antibody or antigen-binding fragment as disclosed herein, a means for inhibiting tumor growth, and a chemical means for linking the PD-L1 binding antibody or antigen-binding fragment to the means for inhibiting tumor growth. For example, the means for inhibiting tumor growth may comprise a means for preventing DNA replication in tumor cells, such as a means that comprises a means for inhibiting topoisomerase I. In some embodiments, the means for inhibiting topoisomerase I comprises a compound represented by:[Formula 1].
[0018] In some embodiments, the chemical means for linking and the means for inhibiting topoisomerase I are represented by:Attorney Docket No.: C1818.70005WO00[Formula 3].
[0019] In some embodiments, the means for inhibiting tumor growth comprises a means for inhibiting tubulin, for example, a means comprising an auristatin. For example, the auristatin may be a compound represented by:[Formula 4],Attorney Docket No.: C1818.70005WO00
[0020] In some embodiments, the chemical means for linking and the auristatin are represented by:[Formula 5].
[0021] In one aspect, provided are PD-L1 -binding antibodies or antigen-binding fragments thereof comprising (a) an immunoglobulin heavy chain variable domain (VH) comprising complementarity-determining (CDR) regions CDR-H1, CDR-H2, and CDR-H3 and (b) an immunoglobulin light chain variable region (VL) comprising CDRs CDR-L1, CDR-L2, and CDR-L3, wherein (i) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 118, 119, and 120, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences SEQ ID NOs: 121, DAS, and SEQ ID NO: 122, respectively; (ii) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 123, 124, and 125, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences SEQ ID NOs: 126, 127, and 128 respectively; or (iii) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 129, 130, and 131, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences SEQ ID NO: 132, DAS, and SEQ ID NO: 133, respectively.
[0022] In some embodiments, the VH comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 134 and the VL comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 135.
[0023] In some embodiments, the VH comprises an amino acid sequence of SEQ ID NO: 134 and the VL comprises an amino acid sequence of SEQ ID NO: 135.
[0024] In some embodiments, the PD-Ll-binding antibody or antigen-binding fragment further comprises an Fc polypeptide, e.g., an IgG Fc polypeptide, such as an IgG selected from the group consisting of IgGl, IgG2, IgG3, and IgG4.Attorney Docket No.: C1818.70005WO00
[0025] In some embodiments, the Fc polypeptide comprises a means for extending the halflife of the antibody or antigen-binding fragment. For example, the half-life extending means may comprise a mutation or set of mutations in the Fc polypeptide. In some embodiments, the set of mutations is selected from the group consisting of M252Y / S254T / T256E (YTE), M428L / N434S (LS), M428L / N434A (LA), H433K / N434F (KF), and L309D / Q311H / N434S (DHS).
[0026] In one aspect, provided are antibody-drug conjugates represented by Ab-Lp-Dq; wherein Ab comprises a PD-L1 -binding antibody or antigen-binding fragment thereof as disclosed herein, L is a linker, D is a drug moiety, p is 1 to 10, and q is 1 to 10. In some embodiments, p and q are equal. For example, p and q may be between 2 and 8, e.g., 2, 4, 6, or 8. In some embodiments, p and q are 4. In some embodiments, p and q are 8. For example, q may be between 2 and 8, e.g., 2, 4, 6, or 8. In some embodiments, q is 4. In some embodiments, q is 8. For example, p may be between 2 and 8, e.g., 2, 4, 6, or 8. In some embodiments, p is 4. In some embodiments, p is 8.
[0027] In some embodiments, D is a drug moiety selected from the group consisting of: maytansinoid, auristatin, anthracycline, calicheamicin, tubulysin, duocarmycin, a topoisomerase inhibitor, a radioisotope, liposome comprising a toxic payload, protein toxin, taxane, indilino-benzodiazepine pseudodimer, and pyrrolobenzodiazepine.
[0028] In some embodiments, D is represented by:[Formula 1].
[0029] In some embodiments, L is represented by the following formula:-L1-L2-Lp-NH-(CH2)n1-Ld-,whereinn1represents an integer of 0 to 6,L1represents -(Succinimid-3-yl-N)-(CH2)n2-C(=O)- wherein n2represents an integer of 2 to 8,Attorney Docket No.: C1818.70005WO00L2represents -NH-(CH2-CH2-O)n5-CH2-CH2-C(=O) or a single bond, wherein n5represents an integer of 1 to 6,Lprepresents a GGFG (SEQ ID NO: 143) tetrapeptide,-NH- (CH2)n1-Ld- is selected from the group consisting of -NH-(CH2)3-C(=O)-, -NH-CH2-O-CH2-C(=O)-, and -NH-(CH2)2-O-CH2-C(=O)-, and-(Succinimid-3-yl-N)- has a structure represented by:[Formula 2],
[0030] In some embodiments, the Lp-Dqcomprises an L-D having structure represented by:[Formula 3].
[0031] In some embodiments, D has a structure represented by:[Formula 4]Attorney Docket No.: C1818.70005WO00
[0032] In some embodiments, the Lp-Dqcomprises an L-D having a structure represented by:[Formula 5].
[0033] In some embodiments, the Lp-Dqis arrived at by reacting a structure represented by:[Formula 5A],
[0034] In some embodiments, provided are antibody conjugates comprising a PD-L1-binding antibody or antigen-binding fragment as disclosed herein, a means for inhibiting tumor growth, and a chemical means for linking the PD-L1 binding antibody or antigen-binding fragment to the means for inhibiting tumor growth. For example, the means for inhibiting tumor growth may comprise a means for preventing DNA replication in tumor cells, such as a means that comprises a means for inhibiting topoisomerase I. In some embodiments, the means for inhibiting topoisomerase I comprises a compound represented by:Attorney Docket No.: C1818.70005WO00[Formula 1].
[0035] In some embodiments, the chemical means for linking and the means for inhibiting topoisomerase I are represented by:[Formula 3].
[0036] In some embodiments, the means for inhibiting tumor growth comprises a means for inhibiting tubulin, for example, a means comprising an auristatin. For example, the auristatin may be a compound represented by:[Formula 4]
[0037] In some embodiments, the chemical means for linking and the auristatin are represented by:Attorney Docket No.: C1818.70005WO00[Formula 5].
[0038] In some embodiments, the chemical means for linking and the auristatin is arrived at by reacting a structure represented by:[Formula 5A],
[0039] In some embodiments, the average number of means for inhibiting tumor growth conjugated per PD-Ll-binding antibody or antigen-binding fragment is from 2 to 8, for example 4 or 8.
[0040] In one aspect, provided are pharmaceutical compositions comprising an effective amount of an antibody-drug conjugate or drug conjugate as disclosed herein and a pharmaceutically acceptable carrier.
[0041] In one aspect, provided are methods of treating, ameliorating, or preventing cancer in a mammalian subject in need thereof, the method comprising a step of administering to the mammalian subject the pharmaceutical composition as disclosed herein. In some embodiments,Attorney Docket No.: C1818.70005WO00the mammalian subject is a primate, such as a human. In some embodiments, the step of administering comprises systemic administration, such as intravenous administration.Attorney Docket No.: C1818.70005WO00DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
[0042] The present disclosure provides, among other things, PD-L1 antibodies and drug conjugates thereof which, in some embodiments, exhibit improved features such as affinity, internalization kinetics, antibody-drug conjugate (ADC) cytotoxicity, tolerability, efficacy, and half-life.Definitions
[0043] As used herein, the terms “about,” “approximately,” and “comparable to,” when used herein in reference to a value, refer to a value that is similar to the referenced value in the context of that referenced value. In general, those skilled in the art, familiar with the context, will appreciate the relevant degree of variance encompassed by "about," “approximately,” and “comparable to” in that context. For example, in some embodiments, the terms "about," “approximately,” and “comparable to” may encompass a range of values that within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the referred value.
[0044] As used herein, the terms “antagonistic,” “neutralizing” or “blocking,” when used in reference to an antibody or antigen-binding fragment thereof, is intended to refer to an antibody or fragment thereof whose binding to its target results in inhibition of at least some of the biological activity of the target.
[0045] As used herein, “antibody” refers to a polypeptide whose amino acid sequence includes immunoglobulins and fragments thereof which specifically bind to a designated antigen, or fragments thereof. Antibodies in accordance with the present invention may be of any type (e.g., IgA, IgD, IgE, IgG, or IgM) or subtype (e.g., IgAl, IgA2, IgGl, IgG2, IgG3, or IgG4). Those of ordinary skill in the art will appreciate that a characteristic sequence or portion of an antibody may include amino acids found in one or more regions of an antibody (e.g., variable region, hypervariable region, constant region, heavy chain, light chain, and combinations thereof). Moreover, those of ordinary skill in the art will appreciate that a characteristic sequence or portion of an antibody may include one or more polypeptide chains, and may include sequence elements found in the same polypeptide chain or in different polypeptide chains.
[0046] “Antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to a form of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs) present on certain cytotoxicAttorney Docket No.: C1818.70005WO00cells (e.g., Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies “arm” the cytotoxic cells and are absolutely required for such killing. The primary cells for mediating ADCC, NK cells, express FcyRIII only, whereas monocytes express FcyRI, FcyRII and FcyRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a molecule, an in vitro ADCC assay, such as that described in U. S. Pat. No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).
[0047] An “antigen-binding fragment” of an antibody, or “antibody fragment” comprises a portion of an intact antibody, which portion is still capable of antigen binding. In some embodiments, the antibody has a function in addition to that of antigen-binding, and an antigenbinding fragment retains that function. Typically, an antigen-binding fragment comprises the variable region of the antibody. Papain digestion of antibodies produces two identical antigenbinding fragments, called “Fab” fragments, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire light chain along with the variable region domain of the heavy chain (VH), and the first constant domain of one heavy chain (CHI). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')2 fragment which roughly corresponds to two disulfide linked Fab fragments having different antigen-binding activity and that is still capable of cross-linking antigen. Fab' fragments differ from Fab fragments by having a few additional residues at the carboxy terminus of the CHI domain, including one or more cysteines from the antibody hinge region. Fab '-SH designates an Fab' in which the cysteine residue(s) of the constant domains bears a free thiol group. F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments having hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0048] As used herein, the term “chimeric antibody” refers to an antibody that has a portion of its heavy and / or light chain identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to correspondingAttorney Docket No.: C1818.70005WO00sequences in antibodies derived from another species or belonging to another antibody class or subclass.
[0049] A “complementarity determining region” (abbreviated “CDR”) is a region of hypervariability interspersed within regions that are more conserved, termed “framework regions” (abbreviated “FR”). In some embodiments, the sequences of the framework regions are identical to the framework regions in human germline sequences. In some embodiments, the sequences of the framework regions are modified with respect to the human germline sequence.
[0050] As used herein, the phrase “complement dependent cytotoxicity” or “CDC” refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), may be performed.
[0051] As used herein, the expression “control sequences” refers to DNA sequences necessary or advantageous for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are typically suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
[0052] As used herein, antibody “effector functions” refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and which typically vary with the antibody isotype. Examples of antibody effector functions include, but are not limited to, Clq binding and complement dependent cytotoxicity, Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis, down regulation of cell surface receptors (e.g., B cell receptors), and B cell activation.
[0053] As used herein, the term “epitope” is an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule, known as the paratope, and which is comprised of the six complementary-determining regions of the antibody. A single antigen may have more than one epitope. Epitopes may be conformational or linear. A conformational epitope is comprised of spatially juxtaposed amino acids from different segments of a linear polypeptide chain. A linear epitope is comprised of adjacent amino acid residues in a polypeptide chain.Attorney Docket No.: C1818.70005WO00
[0054] An Fc fragment comprises the carboxy-terminal portions of both heavy chains held together by disulfides. The effector functions of antibodies are determined by sequences in the Fc region, the region which is also recognized by Fc receptors (FcR) found on certain types of cells.
[0055] As used herein, the term “humanized,” when used in reference to an antibody, refers to a form of a non-human (e.g., murine) antibody that is chimeric. A “humanized antibody” contains minimal sequences derived from non-human immunoglobulin. Typically, humanized antibodies are human immunoglobulins (recipient or acceptor antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having a desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance such as binding affinity. Generally, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin sequence although the framework regions may include one or more amino acid substitutions that improve binding affinity. In some embodiments, no more than six amino acid substitutions in the heavy chain and no more than three amino acid substitutions are used in the light chain in the framework region. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
[0056] As used herein, an “isolated” nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant molecule with which it is ordinarily associated in the natural source of the nucleic acid. An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from nucleic acid molecules as they exist in natural cells.
[0057] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibodyAttorney Docket No.: C1818.70005WO00preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies may be made by a hybridoma method, such as that first described by Kohler et al., Nature 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U. S. Pat. No. 4,816,567). “Monoclonal antibodies” may also be isolated from phage antibody libraries, e.g., using techniques described in Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991).
[0058] As used herein, a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is “operably linked” to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is “operably linked” to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is “operably linked” to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking may be accomplished, e.g., by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers may be used in accordance with conventional practice.
[0059] As used herein, “polypeptide,” which may be used interchangeably with “protein,” refers to a string of at least two amino acids attached to one another by a peptide bond. In some embodiments, a polypeptide may include at least 3-5 amino acids, each of which is attached to others by way of at least one peptide bond. Those of ordinary skill in the art will appreciate that polypeptides can include one or more “non-natural” amino acids or other entities that nonetheless are capable of integrating into a polypeptide chain. In some embodiments, a polypeptide may be glycosylated, e.g., a polypeptide may contain one or more covalently linked sugar moieties. In some embodiments, a single “polypeptide” (e.g., an antibody polypeptide) may comprise two or more individual polypeptide chains, which may in some cases be linked to one another, for example by one or more disulfide bonds or other means.
[0060] As used herein, the phrase “reference level” generally refers to a level considered “normal” for comparison purposes, e.g., a level of an appropriate control. For example, in the context of half-life (e.g., serum half-life) of a protein (e.g., an antibody or antigen-bindingAttorney Docket No.: C1818.70005WO00fragment thereof) a reference level may refer to the half-life of a “reference antibody or antigenbinding fragment thereof’ which may be, e.g., an immunoglobulin of the same class (e.g., IgGl, IgG2, or IgG4) having a wild- type Fc region or an Fc region lacking a half-life extending mutation. In some embodiments, the reference antibody or antigen-binding fragment thereof comprises the same complementarity-determining regions as those of the antibody or antigenbinding fragment thereof (e.g., an antibody or antigen-binding fragment as described herein). In some embodiments, the reference antibody or antigen-binding fragment thereof comprises the same variable regions (e.g., heavy chain and / or light chain variable region) as those of the antibody or antigen-binding fragment thereof (e.g., an antibody or antigen-binding fragment as described herein.)
[0061] As used herein, the phrases “therapeutically effective amount” and “effective amount” are used interchangeably and refer to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount may vary according to factors such as the type of disease (e.g., disease state, age, sex, and / or weight of the individual, and the ability of an antibody (or pharmaceutical composition thereof) to elicit a desired response in the individual. An effective amount may also be an amount for which any toxic or detrimental effects of the antibody or pharmaceutical composition thereof are outweighed by therapeutically beneficial effects.
[0062] As used herein, to “treat” a condition or “treatment” of the condition (e.g., the conditions described herein) is an approach for obtaining beneficial or desired results, such as clinical results. Beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilized (i.e., not worsening) state of disease, disorder, or condition; preventing spread of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable. “Palliating” a disease, disorder, or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.
[0063] As used herein, the term “alkyl” refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, or from one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3-methyl-l -butyl, 2-methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3-Attorney Docket No.: C1818.70005WO00methyl- 1 -pentyl, 4-methyl-l -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alkyl groups, such as heptyl, octyl, and the like. Whenever it appears herein, a numerical range such as “Ci-Ce alkyl” means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, the alkyl is a C1-C10 alkyl, a C1-C9 alkyl, a C1-C8 alkyl, a C1-C7 alkyl, a C1-C6 alkyl, a C1-C5 alkyl, a C1-C4 alkyl, a C1-C3 alkyl, a C1-C2 alkyl, or a C1 alkyl. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.
[0064] As used herein, the term “alkylene” refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.
[0065] As used herein, the term “alkoxy” refers to a straight or branched alkyl group attached to oxygen (alkyl-O-). Exemplary alkoxy groups include, but are not limited to, alkoxy groups of 1-6 or 2-6 carbon atoms, referred to herein as C1-C5alkoxy, C1-C6alkoxy, and C2-C6alkoxy, respectively. Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy, isopropoxy, etc.
[0066] As used herein, the term “aryl” refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems. In some embodiments, the aryl is a 6- to 10-membered aryl. In some embodiments, the aryl is a 6-membered aryl. Aryl radicals include,Attorney Docket No.: C1818.70005WO00but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. In some embodiments, the aryl is phenyl. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen. The term “arylene” refers to a divalent aryl group.
[0067] As used herein, the terms “cycloalkyl,” “carbocyclic,” and “carbocyclo” refer to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a nonaromatic ring atom) or bridged ring systems. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl), from three to ten carbon atoms (C3-C10 cycloalkyl), from three to eight carbon atoms (C3-C8 cycloalkyl), from three to six carbon atoms (C3-C6 cycloalkyl), from three to five carbon atoms (C3-C5 cycloalkyl), or three to four carbon atoms (C3-C4 cycloalkyl). In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl. In some embodiments, the cycloalkyl is a 5-to 6-membered cycloalkyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls or carbocycles include, for example, adamantyl, norbomyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl is optionally substituted with halogen.Attorney Docket No.: C1818.70005WO00
[0068] As used herein, the term “hetero” when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g., heteroaryl, cycloalkenyl, e.g., cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
[0069] As used herein, the terms “heteroaryl” and “heteroaromatic group” refer to an aromatic 5-10 membered ring system containing one or more heteroatoms, for example one to three heteroatoms, such as nitrogen, oxygen, and sulfur. The term may also be used to refer to a 5-6 membered monocyclic heteroaryl, a 5-7 membered monocyclic heteroaryl or an 8-10 membered bicyclic heteroaryl. Where possible, said heteroaryl ring may be linked to the adjacent radical though carbon or nitrogen. Examples of heteroaryl rings include but are not limited to furan, thiophene, pyrrole, pyrrolopyridine, indole, thiazole, oxazole, isothiazole, isoxazole, imidazole, benzoimidazole, imidazopyridine, pyrazole, triazole, pyridine or pyrimidine, etc.
[0070] As used herein, the terms “heterocyclyl,” “heterocycle,” “heterocyclo,” and “heterocyclic group” are art-recognized and refer to saturated or partially unsaturated 4-10 membered ring structures, whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, heterocyclyl rings may be linked to the adjacent radical through carbon or nitrogen. The term may also be used to refer to 4-10 membered saturated or partially unsaturated ring structures that are bridged, fused or spirocyclic ring structures, whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Examples of heterocyclyl groups include, but are not limited to, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, oxetane, azetidine, tetrahydrofuran, dihydrofuran, dihydropyran, tetrahydropyran, etc.
[0071] As used herein, the terms “hydroxy” and “hydroxyl” refer to the radical -OH. As used herein, the terms “halo” and “halogen” as used herein refer to F, Cl, Br, or I. As used herein, the term “oxo” refers to the radical =0. As used herein, the term “cyano” refers to the radical -CN. As used herein, the term “nitro” refers to the radical -NO2.PD-Ll-binding antibodies or antigen-binding fragments thereof
[0072] In one aspect, provided are antibodies (or antigen-binding fragments thereof) that are capable of binding to PD-L1 (“PD-Ll-binding antibodies or antigen-binding fragments thereof’).Attorney Docket No.: C1818.70005WO00
[0073] In some embodiments, the antibodies or fragments thereof are monoclonal antibodies or fragments thereof. In some embodiments, the antibodies or fragments thereof are chimeric antibodies or fragments thereof. In some embodiments, the antibodies or fragments thereof are humanized antibodies or fragments thereof. In some embodiments, the antibodies or antigen-binding fragments are human antibodies or fragments thereof.
[0074] Antigen-binding fragments may be, e.g., an scFv, an Fab, an scFab (single-chain Fab). As used herein, the term “scFv” is used in accordance with its common usage in the art to refer to a single chain in which the VH domain and the VL domain from an antibody are joined, typically via a linker. As used herein, the term “Fab fragment” is used in accordance with its common usage in the art. Fab fragments typically comprise an entire light chain (VL and CLI domains), the variable region domain of the heavy chain (VH), and the first constant domain of one heavy chain (CHI).
[0075] In some embodiments, provided antibodies or antigen-binding fragments thereof comprise a heavy chain variable domain which comprises complementarity determining regions CDR-H1, CDR-H2, and CDR-H3 with sequences as shown Table 1. In some embodiments, provided antibodies or antigen-binding fragments thereof further comprise a light chain variable domain comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 with sequences as shown Table 1.
[0076] In some embodiments, provided antibodies or antigen-binding fragments thereof comprise a heavy chain variable domain with an amino acid sequence as shown in a Table 1. In some embodiments, provided antibodies or antigen-binding fragments thereof comprise a heavy chain variable domain which is a variant of the heavy chain variable sequence shown in Table 1, in that the heavy chain variable domain (VH) has (1) CDR-H1, CDR-H2, and CDR-H3 with sequences as shown in a Table 1 and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH amino acid sequence shown in Table 1.
[0077] In some embodiments, provided antibodies or antigen-binding fragments thereof comprise a heavy chain variable domain with an amino acid sequence as shown in Table 1 and further comprise a light chain variable region which has (1) CDR-L1, CDR-L2, and CDR-L3 with sequences as shown in Table 1 and (2) an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, atAttorney Docket No.: C1818.70005WO00least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the VL sequence shown in Table 1.
[0078] For example, in some embodiments, the disclosure provides antibodies or antigenbinding fragments thereof comprising a heavy chain variable domain which comprises complementarity determining regions CDR-H1, CDR-H2, and CDR-H3 and a light chain variable domain which comprises complementarity determining regions CDR-L1, CDR-L2, and CDR-L3, wherein the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, DAS, SEQ ID NO: 122 respectively; SEQ ID NOs: 123, 124, 125, 126, 127, and 128 respectively; or SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: DAS, and SEQ ID NO: 133 respectively.
[0079] In some embodiments, the heavy chain variable domain has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of SEQ ID NO: 134, and the light chain variable domain has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of SEQ ID NO: 135. In some embodiments, the heavy chain variable domain comprises the sequence of SEQ ID NO: 134, and the light chain variable domain comprises the sequence of SEQ ID NO: 135.
[0080] In some embodiments, antibodies or antigen-binding fragments thereof comprise (1) an immunoglobulin heavy chain having an amino acid sequence at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of SEQ ID NO: 138 and which comprises a heavy chain variable domain having the sequence of SEQ ID NO: 134; and (2) an immunoglobulin light chain having an amino acid sequence at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of SEQ ID NO: 139 and which comprises a light chain variable domain comprising the sequence of SEQ ID NO: 135.
[0081] In some embodiments, antibodies or antigen-binding fragments thereof comprise (1) an immunoglobulin heavy chain having an amino acid sequence of SEQ ID NO: 138 and (2) an immunoglobulin light chain having an amino acid sequence of SEQ ID NO: 139.Attorney Docket No.: C1818.70005WO00
[0082] Table 1. Exemplary sequences of PD-L1 antibodies and fragments thereofAttorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Fc polypeptides
[0083] In some embodiments, PD-L1 -binding antibodies or antigen-binding fragments comprise an immunoglobulin Fc region. Fc regions typically comprise one or more Fc polypeptides, such as a first Fc polypeptide and a second Fc polypeptide. An IgG Fc polypeptide typically contains two constant heavy domains (CH2 and CH3) and a hinge region connected to the CH2 domain. Typical Fc regions comprise two Fc polypeptides which dimerize with one another; however, an Fc region may have a single Fc polypeptide or more than two Fc polypeptides, e.g., as may be present in some antibody formats.
[0084] In some embodiments, provided antibodies or antigen-binding fragments thereof comprise an IgGl Fc region (e.g., human IgGl Fc region), that is, except for having particular residue(s) at certain positions as noted herein, the Fc region has an amino acid sequence that is substantially similar to that of the Fc region within a wild type IgGl Fc. In some embodiments, the wild type IgGl Fc is a human IgGl Fc, in which each Fc polypeptide has an amino acid sequence of SEQ ID NO: 1. In some embodiments, provided antibodies or antigen-binding fragments thereof comprise an Fc region, each Fc polypeptide of which has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of an Fc polypeptide within a wild- type IgGl Fc.
[0085] In some embodiments, provided antibodies or antigen-binding fragments thereof comprise an IgG2 Fc region (e.g., human IgG2 Fc region), that is, except for having particular residue(s) at certain positions as noted herein, the Fc region has an amino acid sequence that is substantially similar to that of the Fc region within a wild type IgG2 Fc. In some embodiments, the wild type IgG2 Fc is a human IgG2 Fc, in which each Fc polypeptide has an amino acid sequence of SEQ ID NO: 2. In some embodiments, provided antibodies or antigen-binding fragments thereof comprise an Fc region, each Fc polypeptide of which has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of an Fc polypeptide within a wild-type IgG2 Fc.
[0086] In some embodiments, provided antibodies or antigen-binding fragments thereof comprise an IgG4 Fc region (e.g., human IgG4 Fc region), that is, except for having particular residue(s) at certain positions as noted herein, the Fc region has an amino acid sequence that isAttorney Docket No.: C1818.70005WO00substantially similar to that of the Fc region within a wild type IgG4 Fc. In some embodiments, the wild type IgG4 Fc is a human IgG4 Fc, in which each Fc polypeptide has an amino acid sequence of SEQ ID NO: 3. In some embodiments, provided antibodies or antigen-binding fragments thereof comprise an Fc region, each Fc polypeptide of which has an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of an Fc polypeptide within a wild-type IgG4 Fc.
[0087] In some embodiments, the Fc region comprises a means for extending the half-life of the antibody or antigen-binding fragment thereof. Examples of such means include Fc modifications (such as amino acid mutations or sets of amino acid mutations), including certain Fc modifications discussed herein.Fc modifications
[0088] In certain embodiments, Fc regions are modified (e.g., substituted) at one more amino acid residues.
[0089] In some embodiments, the Fc region comprises one or more modifications which modify binding to Fc-gamma receptors, e.g., by promoting selective binding, reducing binding, or enhancing binding thereto.
[0090] In certain embodiments, modifications to Fc regions alter the half-life of a molecule (e.g., antibody or antigen-binding fragment thereof) which comprises the Fc region by altering (e.g., enhancing) binding to an Fc receptor such as the neonatal Fc receptor (FcRn). For example, in some embodiments, the Fc region is modified to enhance the half-life of the molecule (e.g., antibody or antigen-binding fragment thereof) which comprises the Fc region. Non-limiting examples of half-life-enhancing mutations or sets of mutations include, e.g., M252Y / S254T / T256E (YTE), M428L / N434S (LS), M428L / N434A (LA), H433K / N434F (KF), and L309D / Q311H / N434S (DHS).
[0091] In some embodiments, modifications to Fc regions prevent Fab arm (e.g., IgG4 Fab arm) exchange. An example of such a modification in the context of an IgG4 Fc region is the S228P mutation.
[0092] In some embodiments, modifications to Fc regions reduce or abrogate effector functions, e.g., Fey receptor-mediated effector functions. Non-limiting examples of effectorreducing mutations or sets of mutations include, e.g., aglycosylation mutations (e.g., N297A or N297Q or N297G), L234A / L235A (for IgGl Fc regions), H268Q / V309L / A330S / P331S (forAttorney Docket No.: C1818.70005WO00IgG2 Fc regions), and V234A / G237A / P238S / H268A / V309L / A330S / P331S (for IgG2 Fc regions).
[0093] In some embodiments, modifications to Fc regions enhance Fey receptor-mediated effector functions. Non-limiting examples of FcyRIIIa effector-enhancing mutations or sets of mutations include, e.g., F243L / R292P / Y300L / V305EP396L, S298A / E333A / K334A, S239D / I332E, S239D / I332E / A330L, and L234Y / L235Q / G236W / S239M / H268D / D270E / S298A in one Fc polypeptide and D270E / K326D / A330M / K334E in another Fc polypeptide.
[0094] In some embodiments, modifications to Fc regions enhance antibody-dependent cellular phagocytosis (ADCP). A non-limiting example of an ADCP-enhancing set of mutations is G236A / S239D / I332E.
[0095] In some embodiments, modifications to Fc regions enhance complement-dependent cytotoxicity (CDC) and / or binding to complement protein Clq. Non-limiting examples of an CDC-enhancing and / or Cl q-binding-enhancing sets of mutations include, e.g., K326W / E333S, S267E / H268F / S324T, and E345R / E430G / S440Y.
[0096] In some embodiments, modifications to Fc regions enhance co-engagement with antigens and Fey receptors. Non-limiting examples of co-engagement-enhancing sets of mutations include, e.g., S267E / L328F and N325S / L328F.
[0097] Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0098] Amino acid sequences of exemplary Fc polypeptide sequences are provided in Tables 2A and 2B.Table 2A. Exemplary Fc polypeptide sequencesAttorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00Table 2B. Further exemplary Fc polypeptide sequencesAttorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00
[0099] In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region comprising one or more modifications in SEQ ID NO: 1 (hlgGl). In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region comprising one or more modifications in SEQ ID NO: 2 (hIgG2). In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region comprising one or more modifications in SEQ ID NO: 3 (hIgG4). In some embodiments, the Fc region comprises an Fc polypeptide whose amino acid sequence has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence according to any one of SEQ ID NOs: 1-3. In some embodiments, the Fc region comprises an amino acid sequence according to any one of SEQ ID NOs: 1-3.
[0100] In certain embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region (“modified Fc region”) with at least one amino acid modification relative to a wild type Fc region. Antibodies or antigen-binding fragments thereof with a modified Fc region may comprise mutations in one Fc polypeptide, or in multiple Fc polypeptide (e.g., when two or more Fc polypeptide are present). Within an antibody or antigen-binding fragment thereof with modifications in multiple Fc polypeptide, the modifications on each Fc polypeptide may be the same or different. In some embodiments the modified Fc region comprises a half-life extending mutation or set of mutations, e.g., M252Y, S254T, and T256E (YTE) and / or M428L and N434S (LS).
[0101] In some embodiments, the modified Fc region comprises a modification selected from the group consisting of: S298A, E333A, K334A, K326A, F243L, R292P, Y300L, V305I,Attorney Docket No.: C1818.70005WO00P396L, F243L, R292P, Y300L, L235V, P396L, F243L, S239D, I332E, A330L, S267E, L328F, D265S, S239E, K326A, A327H, G237F, K326E, G236A, D270L, H268D, S324T, L234F, N325L, V266L, S267D, and combinations thereof. In some embodiments, the modified Fc region comprises a modification selected from the group consisting of S228P, M252Y, S254T, T256E, T256D, T250Q, H285D, T307A, T307Q, T307R, T307W, L309D, Q411H, Q311V, A378V, E380A, M428L, N434A, N434S, N297A, D265A, L234A, L235A, N434W, and combinations thereof.
[0102] In some embodiments, the modified Fc region comprises a specific combination of amino acid substitutions selected from the group consisting of: L234A / L235A; V234A / G237A; L235A / G237A / E318A; S228P / L236E; H268Q / V309L / A330S / A331S; C220S / C226S / C229S / P238S; C226S / C229S / E233P / L235V / L235A; L234F / L235E / P331S; C226S / P230S; L234A / G237A; L234A / L235A / G237A; Q311R / M428L; L234A / L235A / P329G; and combinations thereof.
[0103] In some embodiments, the modified Fc region comprises a specific combination of amino acid substitutions selected from the group consisting of M428L / N434S (LS); M252Y / S254T / T256E (YTE); T250Q / M428L; T307A / E380A / N434A; T256D / T307Q (DQ); T256D / T307W (DW); M252Y / T256D (YD); T307Q / Q311V / A378V (QVV); T256D / H285D / T307R / Q311V / A378V (DDRVV); L309D / Q311H / N434S (DHS); S228P / L235E (SPLE); L234A / L235A (LALA); M428L / N434A (LA); L234A / G237A (LAGA); L234A / L235A / G237A (LALAGA); L234A / L235A / P329G (LALAPG); N297A / YTE; D265A / YTE; LALA / YTE; LAGA / YTE; LALAGA / YTE; LALAPG / YTE; N297A / LS; D265A / LS; LALA / LS; LAGA / LS; LALAGA / LS; LALAPG / LS; N297A / DHS; D265A / DHS; LALA / DHS; LAGA / DHS; LALAGA / DHS; LALAPG / DHS; SP / YTE; SPLE / YTE; SP / LS; SPLE / LS; SP / DHS; SPLE / DHS; N297A / LA; D265A / LA; LALA / LA; LAGA / LA; LALAGA / LA; LALAPG / LA; N297A / N434A; D265A / N434A; LALA / N434A; LAGA / N434A; LALAGA / N434A; LALAPG / N434A; N297A / N434W; D265A / N434W; LALA / N434W; LAGA / N434W; LALAGA / N434W; LALAPG / N434W; N297A / DQ; D265A / DQ; LALA / DQ; LAGA / DQ; LALAGA / DQ; LALAPG / DQ; N297A / DW; D265A / DW; LALA / DW; LAGA / DW; LALAGA / DW; LALAPG / DW; N297A / YD; D265A / YD; LALA / YD; LAGA / YD; LALAGA / YD; LALAPG / YD; N297A / QVV; D265A / QVV; LALA / QVV; LAGA / QVV, LALAGA / QVV; LALAPG / QVV; N297A / DDRVV; D265A / DDRVV; LALA / DDRVV; LAGA / DDRVV; LALAGA / DDRVV; LALAPG / DDRVV; SP / Q311R / M428L; SPLE / Q311R / M428L; N297A / Q311R / M428L; D265A / Q311R / M428L; LALA / Q311R / M428L; LAGA / Q311R / M428L;Attorney Docket No.: C1818.70005WO00LALAGA / Q311R / M428L; LALAPG / Q311R / M428L; and combinations thereof. In some embodiments, the modified Fc region comprises a specific combination of amino acid substitutions selected from the group consisting of M428L / N434S (LS) and M252Y / S254T / T256E (YTE). In some embodiments, the modified Fc region comprises M428L / N434S (LS) (e.g., SEQ ID NO: 19, SEQ ID NO: 36, SEQ ID NO: 43) modifications. In some embodiments, the modified Fc region comprises M252Y / S254T / T256E (YTE) (e.g., SEQ ID NO: 12, SEQ ID NO: 33, SEQ ID NO: 42) modifications.
[0104] In some embodiments, antibodies or antigen-binding fragments thereof include modifications to improve their ability to mediate effector function. Such modifications are known in the art and include afucosylation, or engineering of the affinity of the Fc region towards an activating receptor, mainly FCGR3a for antibody-dependent cellular cytotoxicity (ADCC), and towards Clq for complement-dependent cytotoxicity (CDC).
[0105] In some aspects, an antibody provided herein comprises an Fc region (e.g., an IgGl Fc region) with reduced fucose content at position Asn 297 (EU numbering) compared to a naturally occurring Fc region. Such Fc regions are known to confer improved ADCC activity to the antibodies or antigen-binding fragments thereof which comprise them. In some aspects, such antibodies or antigen-binding fragments thereof do not comprise any fucose at position Asn 297.
[0106] In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region with one or more amino acid substitutions which improve ADCC, such as a substitution at one or more of positions 298, 333, and 334 of an Fc polypeptide. In some embodiments, an antibody or antigen-binding fragment thereof provided herein comprises an Fc region with one or more amino acid substitutions at positions 239, 332, and 330.
[0107] In some embodiments, the Fc region comprises an Fc polypeptide whose amino acid sequence has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence according to any one of SEQ ID NOs: 1-117.
[0108] In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region with at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function.
[0109] In some embodiments, the antibody or antigen-binding fragment thereof comprises one or more alterations that improve or diminish Clq binding and / or CDC.
[0110] In certain embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region with one or more amino acid substitutions, wherein the one or more substitutionsAttorney Docket No.: C1818.70005WO00result in an increase in one or more of antibody half-life, ADCC activity, ADCP activity, or CDC activity compared with a comparable antibody or antigen-binding fragment thereof whose Fc region lacks the one or more substitutions. In certain embodiments, the one or more amino acid substitutions results in increased antibody or antigen-binding fragment thereof half-life at pH 6.0 compared to antibody or antigen-binding fragment thereof comprising a wild-type Fc region. In certain embodiments, the antibody has an increased half-life that is about 10,000-fold, 1,000-fold, 500-fold, 100-fold, 50-fold, 20-fold, 10-fold, 9-fold, 8-fold, 7-fold, 6-fold, 5-fold, 4.5-fold, 4-fold, 3.5-fold, 3-fold, 2.5-fold, 2-fold, 1.95-fold, 1.9-fold, 1.85-fold, 1.8-fold, 1.75-fold, 1.7-fold, 1.65-fold, 1.6-fold, 1.55-fold, 1.50-fold, 1.45-fold, 1.4-fold, 1.35-fold, 1.3-fold, 1.25-fold, 1.2-fold, 1.15-fold, 1.1-fold, or 1.05-fold longer compared to an antibody comprising a wild-type Fc region.
[0111] In certain embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region which comprises one or more amino acid substitutions, wherein the one or more substitutions result in a decrease in one or more of ADCC activity, ADCP activity, or CDC activity compared to a comparable antibody or antigen-binding fragment thereof whose Fc region lacks the one or more substitutions.
[0112] In certain embodiments, the Fc region binds an Fey Receptor selected from the group consisting of: FcyRI, FcyRIIa, FcyRIIb, FcyRIIc, FcyRIIIa, and FcyRIIIb. In certain embodiments, the Fc region binds an Fey Receptor with higher affinity at pH 6.0 compared to an antibody comprising a wild-type Fc region.
[0113] In some embodiments, the antibody or antigen-binding fragment thereof has an extended half-life (i.e., serum half-life) relative to the half-life of a reference antibody or antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof has a half-life of at least about 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, or 52 weeks. In some embodiments, the antibody or antigen-binding fragment thereof has a halflife of more than 52 weeks. In some embodiments, the antibody or antigen-binding fragment thereof has a half-life of at least about 14, 28, 42, 56, 70, 84, 96, or more than 96 days. In some embodiments, the antibody or antigen-binding fragment thereof has a half-life in a range of about 14 days to about 96 days, about 14 days to about 84 days, about 14 days to about 70 days, about 14 days to about 56 days, about 14 days to about 42 days, about 14 days to about 28 days, of about 28 days to about 96 days, about 28 days to about 84 days, about 28 days to about 70 days, about 28 days to about 56 days, about 28 days to about 42 days, of about 42 days to about 96 days, about 42 days to about 84 days, about 42 days to about 70 days, or about 42 days to about 56 days. Methods of measuring half-life are known in the art. In some embodiments, theAttorney Docket No.: C1818.70005WO00half-life is measured in a non-human primate. In some embodiments, the half-life is measured in a human. In some embodiments, the half-life is measured following intravenous administration. In some embodiments, the half-life is measured following subcutaneous administration.
[0114] In some embodiments, the antibody or antigen-binding fragment thereof has a halflife that is at least 20% longer than a reference antibody or antigen-binding fragment thereof. In some embodiments, the half-life of the antibody or antigen-binding fragment thereof is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% longer than the half-life of the reference antibody or antigen-binding fragment thereof. In some embodiments, the half-life of the antibody or antigen-binding fragment thereof is longer than the half-life of the reference antibody or antigen-binding fragment thereof by at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold.Conjugates
[0115] Provided antibody-drug conjugates include those represented by the formula Ab-Lp-Dqin which:- Ab represents a PD-L1 antibody or antigen-binding fragment thereof, as disclosed herein,- L represents a linker, such as a linker described herein,- D represents a drug moiety, such as an anti-tumor compound or moiety as described herein,- p is 1 to 10, and- q is 1 to 10.
[0116] In some embodiments, the -D moieties are the same. In some embodiments, the -D moieties are different.
[0117] In some embodiments, provided conjugates comprise an antibody means for binding PD-L1, an anti-tumor compound, and a chemical means for linking the antibody means to the anti-tumor compound. Non-limiting examples of antibody means for binding PD-L1 include the PD-Ll-binding antibodies and fragments disclosed herein.Attorney Docket No.: C1818.70005WO00
[0118] In some embodiments, provided conjugates comprise (i) a PD-Ll-binding antibody and fragment as disclosed herein (ii) a means for inhibiting tumor growth and (iii) a chemical means for linking the antibody and the means for inhibiting tumor growth.
[0119] In some embodiments, the means for inhibiting tumor growth is a means for preventing DNA replication, such as a means for inhibiting topoisomerase I. Non-limiting examples of means for inhibiting tumor growth include the anti-tumor compounds discussed herein.
[0120] In some embodiments, the means for inhibiting tumor growth is a means for inhibiting tubulin, including anti-tumor compounds described herein.
[0121] Non-limiting examples of chemical means for linking the antibody means to the antitumor compound include the linkers discussed herein.Anti-tumor compounds and moieties
[0122] Anti-tumor compounds and moieties suitable for use in the present disclosure generally exert an anti-tumor effect, e.g., when placed into contact with a tumor cell and / or administered to a subject having a tumor and have a substituent group or a partial structure allowing connecting to a linker structure. Cleavage of the linker in tumor cells may allow release of the anti-tumor compound. In some embodiments, the linker is cleaved at a connecting position to the anti-tumor compound, releasing the anti-tumor compound intact.
[0123] A wide variety of anti-tumor compounds or moieties may be used, including compounds or moieties that inhibit DNA replication, DNA damage agents, tubulin inhibitors, and anti-metabolites.
[0124] Non-limiting examples of inhibitors of DNA replication include anthracyclines (e.g., doxorubicin, daunorubicin, idarubicin, and mitoxantrone), duocarmycins, topoisomerase inhibitors (e.g., inhibitors of topoisomerase I, such as camptothecin or derivatives thereof such as exatecan), mitomycin C, cyclocytidine, platinum-based anti-tumor agents (e.g., cisplatin or derivatives thereof).
[0125] Non-limiting examples of DNA damage agents include calicheamicin, radioisotopes, and bleomycin.
[0126] Non-limiting examples of anti-metabolites include methotrexate.
[0127] Non-limiting examples of tubulin inhibitors include taxanes (e.g., taxol or derivatives thereof, paclitaxel, docetaxel), vinca alkaloids (e.g., vincristine, vinblastine, vindesine, and vinorelbine), colchicine, eribulin, 2-methoxyestradiole, indole derivatives, auristatins, maytansines, and tubulysins.Attorney Docket No.: C1818.70005WO00
[0128] Additional anti-tumor compounds suitable for use in the presently disclosed conjugates include liposomes comprising a toxic payload, protein toxins, indilino-benzodiazepine pseudodimer, and pyrrolobenzodiazepine.
[0129] Derivatives of any of the anti-tumor compounds and moieties mentioned herein may also be suitable.
[0130] In some embodiments, exatecan (a camptothecin derivative and a topoisomerase I inhibitor) (((lS,9S)-l-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-lH,12H-benzo[de]pyrano[3',4':6,7]indolizino[l,2-b]quinoline-10,13(9H,15H)-dione), is the anti-tumor compound. When exatecan is used as part of a conjugate, D may be represented by the following structure:[Formula 1].
[0131] Exatecan can be obtained by known methods. In some embodiments, the amino group at position 1 of Formula 1 is used as a connecting position to the linker. Exatecan can be also released in tumor cells while part of the linker is still attached thereto, and has been observed to exert robust anti-tumor effect even in such cases.
[0132] The number of conjugated anti-tumor compounds per antibody or antigen-binding fragment may be varied according to the embodiment, e.g., to tune the efficacy and / or safety profile of a given conjugate. Conjugates may be produced under defined reaction conditions including using particular amounts of raw materials and reagents. Mixtures containing different numbers of conjugated anti-tumor compounds per conjugate are generally obtained from such reactions. Thus, the number of anti-tumor compounds conjugated in a given antibody or antigen-binding fragment may be expressed or specified by an average value. In some embodiments, the average number of anti-tumor compounds conjugated per an antibody or antigen-binding fragment is about 1 to 10, 2 to 8, or 3 to 8 anti-tumor compounds. Because exatecan has a camptothecin structure, the equilibrium shifts to a structure with a closed lactone ring (closed ring) in an aqueous acidic medium (for example, pH 3 or so) but shifts to a structure with an open lactone ring (open ring) in an aqueous basic medium (forAttorney Docket No.: C1818.70005WO00example, pH 10 or so). Conjugates comprising exatecan either the closed ring structure or the open ring structure are within the scope of the present disclosure.
[0133] In some embodiments, disclosed herein are antibody-drug conjugates (e.g., an antitumor compound conjugated to any antibody or antigen-binding fragment disclosed herein) of the following formula:wherein Ab is an antibody or antigen-binding fragment disclosed herein; andwherein g represents an average DAR; and g is 1 to 10, preferably g is 8.Attorney Docket No.: C1818.70005WO00
[0134] In some embodiments, disclosed herein are antibody-drug conjugates (e.g., an antitumor compound conjugated to any antibody or antigen-binding fragment disclosed herein) of the following formula:wherein Ab is an antibody or antigen-binding fragment disclosed herein; andwherein g represents an average DAR; and g is 8.
[0135] In some embodiments, g is 1-10. In some embodiments, g is 1, 2, 2.5, 3, 3.5, 4, 4.5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, g is 4-8. In some embodiments, g is 7-9 or 7.5-8.5. In some embodiments, g is 8.Attorney Docket No.: C1818.70005WO00
[0136] In one aspect, disclosed herein are antibody-drug conjugates comprising the following Formula:wherein Ab is a PD-L1 -binding antibody or antigen-binding fragment thereof comprising:a heavy chain having the amino acid sequence of SEQ ID NO: 138, anda light chain having the amino acid sequence of SEQ ID NO: 139; andwherein g represents an average drug antibody ratio (DAR); andg is 8.Attorney Docket No.: C1818.70005WO00
[0137] In one aspect, disclosed herein are antibody-drug conjugates comprising the following Formula:wherein Ab is a PD-L1 -binding antibody or antigen-binding fragment thereof comprising:a heavy chain variable domain having a CDR-H1, a CDR-H2, and a CDR-H3 of a heavy chain variable domain comprising the sequence of SEQ ID NO: 134, anda light chain variable domain having a CDR-L1, a CDR-L2, and a CDR-L3 of a light chain variable domain comprising SEQ ID NO: 135; andwherein g represents an average drug antibody ratio (DAR); andg is 8.
[0138] In some embodiments, D is represented by the structure:[Formula 4],
[0139] In some embodiments, disclosed herein are antibody-drug conjugates (e.g., an antitumor compound conjugated to any antibody or antigen-binding fragment disclosed herein) of the following formula:Attorney Docket No.: C1818.70005WO00wherein Ab is an antibody or antigen-binding fragment disclosed herein; andwherein g represents an average DAR; and g is 1 to 10, preferably g is 8.
[0140] In some embodiments, disclosed herein are antibody-drug conjugates (e.g., an antitumor compound conjugated to any antibody or antigen-binding fragment disclosed herein) ofwherein Ab is an antibody or antigen-binding fragment disclosed herein; andwherein g represents an average DAR; and g is 8.Attorney Docket No.: C1818.70005WO00
[0141] In some embodiments, g is 1-10. In some embodiments, g is 1, 2, 2.5, 3, 3.5, 4, 4.5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, g is 4-8. In some embodiments, g is 7-9 or 7.5-8.5. In some embodiments, g is 8.
[0142] In one aspect, disclosed herein are antibody-drug conjugates comprising the following Formula:wherein Ab is a PD-L1 -binding antibody or antigen-binding fragment thereof comprising:a heavy chain having the amino acid sequence of SEQ ID NO: 138, anda light chain having the amino acid sequence of SEQ ID NO: 139; andwherein g represents an average drug antibody ratio (DAR); andg is 8.Attorney Docket No.: C1818.70005WO00
[0143] In one aspect, disclosed herein are antibody-drug conjugates comprising the following Formula:wherein Ab is a PD-L1 -binding antibody or antigen-binding fragment thereof comprising:a heavy chain variable domain having a CDR-H1, a CDR-H2, and a CDR-H3 of a heavy chain variable domain comprising the sequence of SEQ ID NO: 134, anda light chain variable domain having a CDR-L1, a CDR-L2, and a CDR-L3 of a light chain variable domain comprising SEQ ID NO: 135; andwherein g represents an average drug antibody ratio (DAR); andg is 8.Linkers
[0144] In some embodiments, the linker (“L” in the formula Ab-Lp-Dq) has the following structure: -L1-L2-LP-NH— (CH2) n1-La-Lb-Lc-.
[0145] In some embodiments, the antibody or antigen-binding fragment is connected to the terminal of L1(terminal opposite to the connection to L2), and the anti-tumor compound is connected to the terminal of Lc(terminal opposite to the connection to Lb).
[0146] n1represents an integer of 0 to 6 and may be, e.g., an integer of 1 to 5, or 1 to 3.
[0147] L1is a moiety in the linker represented by any of the following structure:-(Succinimid-3-yl-N)— (CH2)n2-C(=O)-,— CH2— C(=O)— NH— (CH2)n3-C(=O)—,Attorney Docket No.: C1818.70005WO00— C(=O)-cyc. Hex(l,4)-CH2 — (N-Succinimid-3-yl)-, or_ C(=O)— (CH2)n4-C(=O)—.
[0148] In the above, n2is an integer of 2 to 8, n3is an integer of 1 to 8, and n4is an integer of 1 to 8.
[0149] In a linker having a structure represented by -(Succinimid-3-yl-N) — (CH2)n2-C(=O)— of L1, “-(Succinimid-3-yl-N) — ” has a structure represented by the following formula:OFo[Formula 2]
[0150] Position 3 of Formula 2 may be a connecting position to the antibody or antigenbinding fragment. The bond to the antibody or antigen-binding fragment at position 3 is characterized by bonding with thioether formation. The nitrogen atom at position 1 of Formula 2 may be connected to the carbon atom of methylene which is present within the linker including the structure. Specifically, -(Succinimid-3-yl-N) — (CH2)n2-C(=O)-L2- is a structure represented by the following formula (herein, “antibody-S-” originates from an antibody or antigen-binding fragment.OAntibody—L N— (CH2)n2— C(=O)-L2—O[Formula 6]
[0151] In Formula 6, n2is an integer of 2 to 8, and preferably 2 to 5. In certain embodiments, n2is 5.
[0152] In a linker having a structure represented by — CH2 — C(=O)— NH— (CH2)n3-C(=O)— of L1, n3is an integer of 1 to 8, preferably 2 to 6. This linker may be connected to an antibody or antigen-binding fragment at the carbon atom of terminal methylene and can have the following structure for connecting by thioether formation, as with the preceding linker (herein, “antibody-S-” originates from an antibody or an antibody or antigen-binding fragment).
[0153] Antibody-S— CH2—C(=O)-NH-(CH2)n3-C(=O)-L2-.Attorney Docket No.: C1818.70005WO00
[0154] In a linker having a structure represented by — C(=O)-cyc. Hex(l,4)-CH2 — (N-Succinimid-3-yl)- of L1, “ — (N-Succinimid-3-yl)-” has a structure represented by the following formula:[Formula 7]
[0155] In Formula 7, the nitrogen atom at position 1 is connected to the carbon atom of methylene present in the linker containing this structure. The carbon atom at position 3 may be connected to the terminal sulfur atom of — S — (CH2)n6-C(=O)— of L2in the linker. This moiety — S — (CH2)n6-C(=O)— of L2in the linker may form a combined linker structure with — C(=O)-cyc. Hex(l,4)-CH2 — (N-Succinimid-3-yl)- of L1in the linker. In the above, cyc. Hex(l,4)-” contained in the linker represents a 1,4-cyclohexylene group. In the linker, — C(=O)-cyc. Hex(l,4)-CH2 — (N-Succinimid-3-yl)- is connected to the antibody or antigenbinding fragment with amide bond formation at its terminal carbonyl carbon (herein, “antibody-NH — ” originates from an antibody or antigen-binding fragment).[Formula 8]
[0156] The amino group of an antibody or antigen-binding fragment for this amide bond formation may be the terminal amino group of a side chain of a lysine residue in an antibody or antigen-binding fragment or an amino group at the N terminal of an antibody or antigenbinding fragment. Said linker can connect by forming an ester bond with the hydroxy group of an amino acid in an antibody or antigen-binding fragment other than such amide bond.
[0157] The structure moiety “-cyc. Hex(l,4)-” contained in the linker may be a divalent saturated cyclic alkylene group other than the 1,4-cyclohexylene group, e.g., a divalent cyclic saturated hydrocarbon group such as a cyclobutylene group, a cyclopentylene group, a cycloheptalene group, or a cyclooctalene group, a divalent aromatic hydrocarbon group such as a phenylene group or a naphthylene group, or a 5- or 6-membered saturated, partially saturated, or aromatic divalent heterocyclic group containing 1 or 2 heteroatoms. Alternatively, this moiety may be a divalent alkylene group having 1 to 4 carbon atoms. The connection to the divalent group may occur at adjacent positions or at distant positions.Attorney Docket No.: C1818.70005WO00
[0158] In a linker having a structure represented by — C(=O)— (CH2)n4-C(=O)— as L1, n4is an integer of 1 to 8, and preferably 2 to 6. This linker may also be connected by amide bond formation at its terminal carbonyl group with an amino group of the antibody or antigenbinding fragment, as with the linkers mentioned above (see the following formula; in the structure thereof, “antibody-NH-” originates from an antibody or antigen-binding fragment).
[0159] Antibody-NH— C(=O)-(CH2)n4-C(=O)-L2-.
[0160] Specific examples of L1in the linker can include-(Succinimid-3-yl-N) — CH2CH2 — C(=O)—-(Succinimid-3-yl-N) — CH2CH2CH2 — C(=O)—-(Succinimid-3-yl-N)— CH2CH2CH2CH2— C(=O)- -(Succinimid-3-yl-N)— CH2CH2CH2CH2CH2— C(=O)- — CH2C(=O)NH-CH2— C(=O)—,— CH2C(=O)NH-CH2CH2— C(=O)—— CH2C(=O)NH-CH2CH2CH2— C(=O)—— CH2C(=O)NH-CH2CH2CH2CH2— C(=O)- — CH2C(=O)NH-CH2CH2CH2CH2CH2— C(=O)- — C(=O)-cyc. Hex(l,4)-CH2— (N-Succinimid-3-yl)- — C (=0) - Aryl-CH2— (N - Succinimid- 3 -yl) - — C (=0) -eye. Het-CH2— (N - Succinimid- 3 -yl) - _ C(=O)-CH2CH2— C(=O)—— C(=O) -CH2CH2CH2— C(=O) - _ C(=O)— CH2CH2CH2CH2— C(=O)—_ C(=O)— CH2CH2CH2CH2CH2— C(=O)—— C(=O) -CH2CH2CH2CH2CH2CH2— C(=O)
[0161] (Aryl represents a divalent aromatic hydrocarbon group, and cyc. Het represents a divalent cyclic heterocyclic group).
[0162] L2may be a linker represented by the following structure:— NH— (CH2CH2O)n5-CH2— CH2— C(=O)-, or— S— (CH2)n6-C(=O)—.
[0163] In some embodiments, L2is a single bond. In the above, n5is an integer of 1 to 6, and n6is an integer of 1 to 6.Attorney Docket No.: C1818.70005WO00
[0164] In a linker having a structure of — NH — (CH2CH2O)n5-CH2 — CH2 — C(=O)— as L2, n5is an integer of 1 to 6, and preferably 2 to 4. This moiety in the linker is connected to L1at its terminal amino group and is connected to Lpat its carbonyl group at the other terminal.
[0165] In a linker having a structure of — S — (CH2)n6-C(=O)— as L2, n6is an integer of 1 to 6, and preferably 2 to 4.
[0166] Specific non-limiting examples of L2can include— NH— CH2CH2O— CH2CH2— C(=O)—,— NH— CH2CH2O— CH2CH2O— CH2CH2— C(=O)-,— NH— CH2CH2O— CH2CH2— CH2CH2O— CH2CH2— C(=O)-,— NH— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2— C(=O)-, — NH— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2— C(=O)—,— NH— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2O— CH2CH2— C(=O)—.
[0167] When L2is — S — (CH2)n6-C(=O)—, L’ to be combined therewith is — C(=O)-cyc. Hex(l,4)-CH2 — (N-Succinimid-3-yl)-. Specific examples of -L1-L2- can include —C(=O)-cyc. Hex(l,4)-CH2—(N-Succinimid-3-yl)-S—CH2—C(=O)— —C(=O)-cyc. Hex(l,4)-CH2—(N-Succinimid-3-yl)-S—CH2CH2-C—(=O)- —C(=O)-cyc. Hex(l,4)-CH2—(N-Succinimid-3-yl)-S—CH2CH2CH2—C(=O)- —C(=O)-cyc. Hex(l,4)-CH2—(N-Succinimid-3-yl)-S—CH2CH2CH2CH2— C(=O)- — C(=O)-cyc. Hex(l,4)-CH2— (N-Succinimid-3-yl)-S— CH2CH2CH2CH2CH2— C(=O)- — C(=O)-cyc. Hex(l,4)-CH2 — (N-Succinimid-3-yl)-S — CH2CH2CH2CH2CH2CH2— C(=O)—.
[0168] Linker Lpmay be a peptide residue consisting of 2 to 7 amino acids. Specifically, Lpmay consist of or comprise an oligopeptide residue in which 2 to 6 amino acids are linked by a peptide bond. Lpmay be connected to L2at its N terminal and may be connected to the amino group of — NH — (CH2)n1-La-Lb-Lc-moiety of the linker at its C terminal. Amino acid residues within Lpin the linker may be L- or a D-amino acid residues, preferably L-amino acid residues. Amino acid residues such as P-alanine, e-aminocaproic acid, or y-aminobutyric acid in addition to a-amino acids can also be included, as well as non-natural type amino acid residues such as N-methylated amino acid residues.Attorney Docket No.: C1818.70005WO00
[0169] Examples of suitable amino acid residues include phenylalanine (Phe; F), tyrosine (Tyr; Y), leucine (Leu; L), glycine (Gly; G), alanine (Ala; A), valine (Vai; V), lysine (Lys; K), citrulline (Cit), serine (Ser; S), glutamic acid (Glu; E), and aspartic acid (Asp; D). In some embodiments, Lpincludes one or more amino acid residues selected from the group consisting of phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid. In some embodiments, release of the anti-tumor compound can be controlled by altering the sequence of Lp. In some embodiments, the number of amino acid residues in Lpis between 2
[0170] Non-limiting examples of sequences for Lpinclude:-GGF- -DGGF- (SEQ ID NO: 140)-(D-)D-GGF- (SEQ ID NO: 141)-EGGF- (SEQ ID NO: 142)-GGFG- (SEQ ID NO: 143)-SGGF- (SEQ ID NO: 144)-KGGF- (SEQ ID NO: 145)-DGGFG- (SEQ ID NO: 146)-GGFGG- (SEQ ID NO: 147)-DDGGFG- (SEQ ID NO: 148)-KDGGFG- (SEQ ID NO: 149)-GGFGGGF- (SEQ ID NO: 150).
[0171] In the above, “(D-)D” represents a D-aspartic acid. In some embodiments, Lpis - GGFG- (SEQ ID NO: 143).
[0172] In a structure represented by — NH — (CH2)n ’- within the linker, n1can be an integer of 0 to 6, e.g., an integer of 1 to 5, and more preferably 1 to 3. The amino group of this moiety can be connected to the C terminal of Lpin the linker.
[0173] Lacan be represented by any of structures — C(=O)— NH—, —NR1— (CH2)n7-, and — O — or can be a single bond. In the above, n7may be an integer of 1 to 6, R1may be a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, — (CH2)n8-COOH, or — (CH2)n9-OH, n8may be an integer of 1 to 4, and n9may be an integer of 1 to 6.
[0174] The amide structure — C(=O)— NH— within linker Lamay be connected to Lbat its nitrogen atom side. In the structure moiety of — NR1— (CH2)n7- within La, n7may be an integer of 1 to 6, for example, 1 to 3. This moiety may be connected to Lbat its methylene side. R1mayAttorney Docket No.: C1818.70005WO00be a hydrogen atom or an alkyl group having 1 to 6 carbon atoms. The alkyl group having 1 to 6 carbon atoms may be linear or branched. Examples thereof can include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a 2-methylbutyl group, a neopentyl group, a 1 -ethylpropyl group, a hexyl group, an isohexyl group, a 4-methylpentyl group, a 3 -methylpentyl group, a 2-methylpentyl group, a 1 -methylpentyl group, a 3,3-dimethylbutyl group, a 2,2-dimethylbutyl group, a 1,1 -dimethylbutyl group, a 1,2-dimethylbutyl group, a 1,3-dimethylbutyl group, a 2,3-dimethylbutyl group, and a 2-ethylbutyl group. Of them, a methyl group or an ethyl group is preferred. When R1has a structure represented by — (CH2)n8-COOH, n8may be an integer of 1 to 4, for example, 1 or 2. When R1has a structure represented by — (CH2)n9-OH, n9may be an integer of 1 to 6, and preferably 1 or 2. R1may be, for example, a hydrogen atom, a methyl group, an ethyl group, — CH2COOH, — CH2CH2 — COOH, or — CH2CH2 — OH, and more preferably a hydrogen atom, a methyl group, or — CH2COOH. In some embodiments, R1is a hydrogen atom. The Lamoiety of the linker may be — O — or a single bond.
[0175] Lbcan be any of structures — CR2( — R3) —, — O —, and — NR4— or is a single bond. In the above, R2and R3each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, — (CH2)na-NH2, — (CH2)nb-COOH, or — (CH2)nc-OH, R4is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, nais an integer of 0 to 6, nbis an integer of 1 to 4, and ncis an integer of 0 to 4. When naor ncis 0, R2and R3are not the same each other.
[0176] When each of R2and R3is an alkyl group, this alkyl group is interpreted as defined in the alkyl group of R1. When R2and R3has a structure of — (CH2)na-NH2, nais an integer of 0 to 6, and preferably 0, or is 3 to 5. When nais 0, R2and R3are not the same as each other. When R2and R3has a structure of — (CH2)nb-COOH, nbis an integer of 1 to 4, for example, 1 or 2. When R2and R3has a structure of — (CH2)nc-OH, ncis an integer of 0 to 4, and preferably 1 or 2.
[0177] Each of R2and R3may be independently a hydrogen atom, a methyl group, an ethyl group, — NH2, — CH2CH2CH2NH2, — CH2CH2CH2CH2NH2, — CH2CH2CH2CH2CH2CH2NH2, — CH2COOH, — CH2CH2— COOH, — CH2OH, or — CH2CH2 — OH. In some embodiments, R2and R3are independently a hydrogen atom, a methyl group, — NH2, — CH2CH2CH2CH2NH2, — CH2COOH, — CH2CH2— COOH, — CH2OH, or — CH2CH2 — OH. In some embodiments, R2and R3are hydrogen atoms.Attorney Docket No.: C1818.70005WO00
[0178] When R4is an alkyl group having 1 to 6 carbon atoms, this alkyl group is interpreted as defined in the alkyl group of R1. R4is preferably a hydrogen atom or a methyl group, and more preferably a hydrogen atom.
[0179] Non-limiting examples of the structure represented by— NH — (CH2)n1-La-Lb- as the linker include:— NH— CH2—— NH— CH(CH3)- — NH— C(CH3)2- — NH— CH2— CH(CH3)- — NH— CH(— CH2OH)—— NH— CH(— CH2COOH)—— NH— CH(— CH2CH2COOH)—— NH— CH(— CH2CH2CH2CH2NH2)—— NH— CH2CH2——NH—CH2—O—CH2—— NH— CH2CH2— O—— NH— CH2CH2— O— CH2—— NH— CH2CH2C(CH3)2- — NH— CH2CH2NH—— NH— CH2CH2NH— CH2—— NH— CH2CH2N(CH3)-CH2——NH—CH2CH2NH—CH2CH2——NH—CH2CH2N(CH3)-CH2CH2—— NH— CH2CH2N(— CH2COOH)— CH2—— NH— CH2CH2N(— CH2CH2OH)— CH2—— NH— CH2CH2N(— CH2CH2OH)— CH2CH2—— NH— CH2CH2CH2C(=O)-NHCH(-CH2OH)—— NH— CH2CH2CH2C(=O)-NHCH(-CH2COOH)—— NH— CH2CH2CH2C(=O)-NHCH(-CH2CH2CH2CH2NH2)—— NH— CH2CH2CH2—— NH— CH2CH2CH2CH2—— NH— CH2CH2CH2CH2CH2—— NH— CH2CH2CH2CH2CH(NH2)—.Attorney Docket No.: C1818.70005WO00
[0180] In some embodiments, — NH — (CH2)n1-La-Lb- has one of the following structures:— NH— CH2—— NH— CH2— CH(CH3)- — NH— CH(— CH2OH)—— NH— CH(— CH2CH2COOH)—— NH— CH2CH2—— NH— CH2— O— CH2—— NH— CH2CH2— O—— NH— CH2CH2— O— CH2—— NH— CH2CH2C(CH3)2- — NH— CH2CH2NH—— NH— CH2CH2NH— CH2——NH—CH2CH2N(CH3)-CH2——NH—CH2CH2N(CH3)-CH2CH2—— NH— CH2CH2N(— CH2COOH)— CH2—— NH— CH2CH2N(— CH2CH2OH)— CH2—— NH— CH2CH2N(— CH2CH2OH)— CH2CH2—— NH— CH2CH2CH2C(=O)-NHCH(-CH2OH)—— NH— CH2CH2CH2C(=O)-NHCH(-CH2COOH)—— NH— CH2CH2CH2—— NH— CH2CH2CH2CH2—— NH— CH2CH2CH2CH2CH2—.
[0181] In some embodiments, — NH — (CH2)n1-La-Lb- has one of the following structures:— NH— CH2—— NH— CH2CH2—— NH— CH2— O— CH2—— NH— CH2CH2— O—— NH— CH2CH2— O— CH2—— NH— CH2CH2NH—— NH— CH2CH2NH— CH2—— NH— CH2CH2N(— CH2COOH)— CH2— —NH—CH2CH2N(—CH2CH2OH)—CH2CH2—— NH— CH2CH2CH2C(=O)— NHCH(— CH2COOH)—Attorney Docket No.: C1818.70005WO00— NH— CH2CH2CH2—— NH— CH2CH2CH2CH2—— NH— CH2CH2CH2CH2CH2—.
[0182] In some embodiments, — NH — (CH2)n1-La-Lb- has one of the following structures:— NH— CH2— O— CH2—, and— NH— (CH2)2— O— CH2—.
[0183] Lccan be — CH2 — or — C(=O)—. Said linker can be connected to the anti-tumor compound. In some embodiments, Lc— C(=O)—.
[0184] The chain length of — NH — (CH2)n1-La-Lb-Lccan be a chain length of 4 to 7 atoms, for example, a chain length of 5 or 6 atoms.
[0185] When a conjugate as disclosed herein is transferred to the inside of a cell, e.g., a tumor cells, the linker moiety may be cleaved and an anti-tumor compound derivative having a structure represented by NH2 — (CH2)n1-La-Lb-Lc-(NH-DX) and having anti-tumor properties may be released. Examples of such anti-tumor derivatives include an anti-tumor derivative having a structure moiety in which the structure represented by — NH — (CH2)n1-La-Lb- of the linker is bound with Lcand has a terminal amino group. Non-limiting examples of anti-tumor compound derivative structures include the following:NH2— CH2CH2— C(=O)-(NH-DX)NH2— CH2CH2CH2— C(=O)-(NH-DX)NH2— CH2— O— CH2— C(=O)-(NH-DX)NH2— CH2CH2— O— CH2— C(=O)-(NH-DX).
[0186] Without being bound by any particular theory, the structure NH2 — CH2 — O — CH2 — C(=O)— (NH-DX) undergoes self-degradation to release the following HO— CH2 — C(=O)— (NH-DX). Those compounds can also be used as a production intermediate of conjugates of the present disclosure.
[0187] For conjugates in which exatecan is used as an anti-tumor compound, in some embodiments, the anti-tumor compound-linker has the following structure [-L1-L2-LP-NH — (CH2)n1-La-Lb-Lc- (NH-DX)]. In some embodiments, the average conjugated number of the drug-linker structure moieties per antibody or antigen-binding fragment is from 1 to 10, from 2 to 8, or more from 3 to 8. In some embodiments, the average conjugated number of the druglinker structure moieties per antibody or antigen-binding fragment is 8.
[0188] Non-limiting examples of anti-tumor compound-linker structures include:Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00
[0189] In some embodiments, the anti-tumor compound-linker structure is one of the following:Attorney Docket No.: C1818.70005WO00
[0190] In some embodiments, the anti-tumor compound-linker structure is one of the following:
[0191] In some embodiments, the linker has one of the following structures, with the left terminal of any of the following structures is a connecting position with the antibody or antigenbinding fragment and the right terminal is a connecting position with the anti-tumor compound.Attorney Docket No.: C1818.70005WO00Attorney Docket No.: C1818.70005WO00
[0192] In some embodiments, the linker has one of the following structures,Attorney Docket No.: C1818.70005WO00
[0193] In some embodiments, the linker has one of the following structures:
[0194] In some embodiments, the linker (“L” in the formula Ab-Lp-Dq) has the following formula: Aa-Ww-Yy, wherein:-A- is a Stretcher unit;a is 0 or 1;each — W — is independently an Amino Acid unit;Attorney Docket No.: C1818.70005WO00w is independently an integer ranging from 0 to 12;— Y — is a Spacer unit; andy is 0, 1 or 2.Stretcher unit
[0195] The Stretcher unit (-A-), when present, is capable of linking a ligand (such an antibody or antigen-binding fragment thereof) to an amino acid unit ( — W — ). In some embodiments, the ligand has a functional group that can form a bond with a functional group of a Stretcher. Useful functional groups that can be present on a ligand, either naturally or via chemical manipulation include, but are not limited to, sulfhydryl ( — SH), amino, hydroxyl, carboxy, the anomeric hydroxyl group of a carbohydrate, and carboxyl. In one aspect, the ligand functional groups are sulfhydryl and amino. Sulfhydryl groups can be generated by reduction of an intramolecular disulfide bond of a ligand. Alternatively, sulfhydryl groups can be generated by reaction of an amino group of a lysine moiety of a ligand using 2-iminothiolane (Traut's reagent) or another sulfhydryl generating reagent.
[0196] In one embodiment, the Stretcher unit forms a bond with a sulfur atom of the ligand. The sulfur atom can be derived from a sulfhydryl group of a ligand. Representative Stretcher units of this embodiment are depicted within the square brackets of Formulas 6 and 7, wherein L-, — W —, — Y —, -D, w and y are as defined above, and R17is selected from — Ci-Cio alkylene-, — C3-C8 carbocyclo-, — O — (Ci-Cs alkyl)-, -arylene-, — Ci-Cio alkylenearylene-, -arylene-Ci-Cio alkylene-, — Ci-Cioalkylene-(C3-Cs carbocyclo)-, — (C3-Cs carbocyclo)-Ci-Cio alkylene-, — C3-C8 heterocyclo-, — C1-C10 alkylene-(C3- Cs heterocyclo)-, — (C3-C8heterocyclo)-Ci-Cio alkylene-, — (CH2CH2O)r—, and — (CH2CH2O)r— CH2—; and r is an integer ranging from 1-10.[Formula 10]
[0197] An illustrative Stretcher unit is that of Formula 9 wherein R17is — (CH2)5:Attorney Docket No.: C1818.70005WO00
[0198] Another illustrative Stretcher unit is that of Formula 9 wherein R17is — (CH2CH2O)r— CH2—; and r is 2:
[0199] Still another illustrative Stretcher unit is that of Formula 9 wherein R17is — (CH2)5 —
[0200] In some embodiments, the Stretcher unit is linked to the ligand (e.g., an antibody or antigen-binding fragment thereof) via a disulfide bond between a sulfur atom of the ligand and a sulfur atom of the Stretcher unit. A representative Stretcher unit of this embodiment is depicted within the square brackets of Formula 11, wherein R17, L-, — W —, — Y —, -D, w and y are as defined above.L-|-S— R17— C(O)-]- Ww— Yy— D[Formula 11]
[0201] In yet another embodiment, the reactive group of the Stretcher contains a reactive site that can form a bond with a primary or secondary amino group of a ligand (e.g., antibody or antigen-binding fragment thereof). Non-limiting examples of these reactive sites include, but are not limited to, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates and isothiocyanates. Representative Stretcher units of this embodiment are depicted within the square brackets of Formulas 12 and 13, wherein — R17—, L-, — W —, — Y —, -D, w and y are as defined above.[Formula 12]SL-|-C— N— R17— C(O)-]- Ww— Yy— DAttorney Docket No.: C1818.70005WO00[Formula 13]
[0202] In yet another aspect, the reactive group of the Stretcher contains a reactive site that is reactive to a modified carbohydrate ( — CHO) group that can be present on a ligand (e.g., antibody or antigen-binding fragment thereof). For example, a carbohydrate can be mildly oxidized using a reagent such as sodium periodate and the resulting ( — CHO) unit of the oxidized carbohydrate can be condensed with a Stretcher that contains a functionality such as a hydrazide, an oxime, a primary or secondary amine, a hydrazine, a thiosemicarbazone, a hydrazine carboxylate, and an arylhydrazide such as those described by Kaneko, T. et al. (1991) Bioconjugate Chem 2:133-41. Representative Stretcher units of this embodiment are depicted within the square brackets of Formulas 14, 15, and 16, wherein — R17—, L-, — W —, — Y —, -D, w and y are as defined above.[Formula 16]Amino acid unit
[0203] The Amino Acid unit ( — W — ), when present, links the Stretcher unit to the Spacer unit if the Spacer unit is present, links the Stretcher unit to the Drug moiety if the Spacer unit is absent, and links the Ligand unit to the Drug unit if the Stretcher unit and Spacer unit are absent. Ww— is a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit. Each — W — unit independently has the formula denoted below in the square brackets, and w is an integer ranging from 0 to 12:Attorney Docket No.: C1818.70005WO00
[0204] wherein R19is hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, — CH2OH, — CH(OH)CH3, — CH2CH2SCH3, — CH2CONH2, — CH2COOH, — CH2CH2CONH2, — CH2CH2COOH, — (CH2)3NHC(=NH)NH2, — (CH2)3NH2, — (CH2)3NHCOCH3, — (CH2)3NHCHO, — (CH2)4NHC(=NH)NH2, — (CH2)4NH2, — (CH2)4NHCOCH3, — (CH2)4NHCHO, — (CH2)3NHCONH2, — (CH2)4NHCONH2, — CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3 -pyridylmethyl-,
[0205] The Amino Acid unit can be enzymatically cleaved by one or more enzymes, including a tumor-associated protease, to liberate the Drug unit (-D), which in one embodiment is protonated in vivo upon release to provide a Drug (D).
[0206] Illustrative Wwunits are represented by Formulas 17-19:[Formula 17]wherein R20and R21are as follows:R20R21Benzyl (CH2)4NH2;Methyl (CH2)4NH2;Isopropyl (CH2)4NH2;Isopropyl (CH2)3NHCONH2;Attorney Docket No.: C1818.70005WO00Benzyl (CH2)3NHCONH2;Isobutyl (CH2)3NHCONH2;sec-butyl (CH2)3NHCONH2;[Formula 18]wherein R20, R21and R22are as follows:R20 Pi2' R22Benzyl Benzyl (CH2)4NH2;Isopropyl Benzyl (CH2)4NH2; andH Benzyl (CH2)4NH2;[Formula 19]wherein R20, R21, R22and R23are as follows:R20 Pi2' R22R23H benzyl isobutyl H; andmethyl isobutyl methyl isobutyl.
[0207] Exemplary Amino Acid units include, but are not limited to, units of formula (VII) where: R20is benzyl and R21is — (CH2)4NH2; R20isopropyl and R21is — (CH2)4NH2; R20isopropyl and R21is — (CH2)3NHCONH2. Another exemplary Amino Acid unit is a unit of formula (VIII) wherein R20is benzyl, R21is benzyl, and R22is — (CH2)4NH2.Attorney Docket No.: C1818.70005WO00
[0208] Useful — Ww— units can be designed and optimized in their selectivity for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease. In one embodiment, a — Ww— unit is that whose cleavage is catalyzed by cathepsin B, C and D, or a plasmin protease.
[0209] In one embodiment, — Ww— is a dipeptide, tripeptide, tetrapeptide or pentapeptide.
[0210] When R19, R20, R21, R22or R23 is other than hydrogen, the carbon atom to which R19, R20, R21, R22or R23is attached is chiral.
[0211] Each carbon atom to which R19, R20, R21, R22or R23is attached is independently in the (S) or (R) configuration.
[0212] In one aspect of the Amino Acid unit, the Amino Acid unit is valine-citrulline. In another aspect, the Amino Acid unit is phenylalanine-lysine (FK). In yet another aspect of the Amino Acid unit, the Amino Acid unit is N-methylvaline-citrulline. In yet another aspect, the Amino Acid unit is 5 -amino valeric acid, homo phenylalanine lysine, tetraisoquinolinecarboxylate lysine, cyclohexylalanine lysine, isonipecotic acid lysine, betaalanine lysine, glycine serine valine glutamine and isonipecotic acid.
[0213] In certain embodiments, the Amino Acid unit can comprise natural amino acids. In other embodiments, the Amino Acid unit can comprise non-natural amino acids.Spacer unit
[0214] The Spacer unit ( — Y — ), when present, links an Amino Acid unit to the drug moiety (D within the formula Ab-Lp-Dq) when an Amino Acid unit is present. Alternately, the Spacer unit links the Stretcher unit to the drug moiety when the Amino Acid unit is absent. The Spacer unit also links the drug moiety to the PD-L1 antibody or antigen-binding fragment thereof when both the Amino Acid unit and Stretcher unit are absent.
[0215] Spacer units are of two general types: self-immolative and non self-immolative. A non self-immolative Spacer unit is one in which part or all of the Spacer unit remains bound to the drug moiety after cleavage, particularly enzymatic, of an Amino Acid unit from a conjugate. Examples of a non self-immolative Spacer unit include, but are not limited to a (glycineglycine) Spacer unit and a glycine Spacer unit. When an Exemplary Compound containing a glycine-glycine Spacer unit or a glycine Spacer unit undergoes enzymatic cleavage via a tumorcell associated-protease, a cancer-cell-associated protease or a lymphocyte-associated protease, a glycine-glycine-Drug moiety or a glycine-Drug moiety is cleaved from L-Aa-Ww-. In one embodiment, an independent hydrolysis reaction takes place within the target cell, cleaving the glycine — Drug moiety bond and liberating the Drug.Attorney Docket No.: C1818.70005WO00
[0216] In another embodiment, — Yy— is a p-aminobenzyl alcohol (PAB) unit whose phenylene portion is substituted with Qmwherein Q is — Ci-Cs alkyl, — O — (Ci-Cs alkyl), -halogen, -nitro or -cyano; and m is an integer ranging from 0-4.
[0217] In one embodiment, a non self-immolative Spacer unit ( — Y — ) is -Gly-Gly-.
[0218] In another embodiment, a non self-immolative the Spacer unit ( — Y — ) is -Gly-.
[0219] In one embodiment, a Drug-Linker Compound or a Drug-Linker Ligand Conjugate is provided in which the Spacer unit is absent (y=0), or a pharmaceutically acceptable salt or solvate thereof.
[0220] Alternatively, an Exemplary Compound containing a self-immolative Spacer unit can release -D without the need for a separate hydrolysis step. In this embodiment, — Y — is a PAB group that is linked to — Ww— via the amino nitrogen atom of the PAB group, and connected directly to -D via a carbonate, carbamate or ether group.
[0221] Other examples of self-immolative spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group such as 2-aminoimidazol-5-methanol derivatives (Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237) and ortho or paraaminobenzylacetals. Spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al., Chemistry Biology, 1995, 2, 223), appropriately substituted bicyclo[2.2.1] andbicyclo[2.2.2] ring systems (Storm, et al., J. Amer. Chem. Soc., 1972, 94, 5815) and 2-aminophenylpropionic acid amides (Amsberry, et al., J. Org. Chem., 1990, 55, 5867). Elimination of amine-containing drugs that are substituted at the a-position of glycine (Kingsbury, et al., J. Med. Chem., 1984, 27, 1447) are also examples of self-immolative spacer useful in Exemplary Compounds.
[0222] In one embodiment, the Spacer unit is a branched bis(hydroxymethyl)styrene (BHMS) unit, which can be used to incorporate and release multiple drugs.
[0223] In one aspect, Spacer units ( — Yy— ) are represented by Formulas 20-22:[Formula 20]wherein Q is — Ci-Cs alkyl, — O — (Ci-Cs alkyl), -halogen, -nitro or -cyano; and m is an integer ranging from 0-4;Attorney Docket No.: C1818.70005WO00[Formula 22],Exemplary linker-drug combinations
[0224] In some embodiments, the -Lp-Dqcomprises an -E-D is represented by the following structure:[Formula 3].
[0225] In some embodiments, the -Lp-Dqcomprises an -L-D is represented by the following structure:Attorney Docket No.: C1818.70005WO00[Formula 5].Pharmaceutical Compositions
[0226] The present disclosure also includes pharmaceutical compositions that contain therapeutically effective amounts of an antibody, antigen-binding fragment, or antibody-drug conjugate as disclosed herein. Compositions can be formulated for use in a variety of drug delivery systems. One or more physiologically acceptable excipients or carriers can also be included in the composition for proper formulation. Suitable formulations for use in the present disclosure are found in Remington’s Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, e.g., Langer (Science 249:1527-1533, 1990).
[0227] In some embodiments, a pharmaceutical composition may contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen- sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, betacyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifyingAttorney Docket No.: C1818.70005WO00agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (such as sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and / or pharmaceutical adjuvants (see, Remington’s Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990)).
[0228] In some embodiments, a pharmaceutical composition is citrate-free.
[0229] In some embodiments, a pharmaceutical composition contains nanoparticles, e.g., polymeric nanoparticles, liposomes, or micelles.
[0230] In some embodiments, a pharmaceutical composition contains a sustained- or controlled-delivery formulation. Techniques for formulating sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Sustained-release preparations may include, e.g., porous polymeric microparticles or semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained release matrices may include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly (2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. Sustained release compositions may also include liposomes that can be prepared by any of several methods known in the art.
[0231] Pharmaceutical compositions containing an antibody or antigen-binding fragment disclosed herein can be presented in a dosage unit form and can be prepared by any suitable method. A pharmaceutical composition should be formulated to be compatible with its intended route of administration, as discussed further herein in the “Methods of Treatment” section.
[0232] Useful formulations can be prepared by methods known in the pharmaceutical art. For example, see Remington ’s Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990). Formulation components suitable for parenteral administration include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such asAttorney Docket No.: C1818.70005WO00EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. In some embodiments, the formulation for parenteral administration is citrate-free.
[0233] For intravenous or subcutaneous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier should be stable under the conditions of manufacture and storage, and should be preserved against microorganisms. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.
[0234] An intravenous or subcutaneous drug delivery formulation may be contained in a syringe, pen, or bag. In some embodiments, the bag is connected to a channel comprising a tube and / or a needle. In some embodiments, the formulation is a lyophilized formulation or a liquid formulation.
[0235] These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as-is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
[0236] A polyol, which acts as a tonicifier and may stabilize an antibody or antigen-binding fragment, may also be included in the formulation. The polyol is added to the formulation in an amount which may vary with respect to the desired isotonicity of the formulation. In some embodiments, the aqueous formulation is isotonic. The amount of polyol added may also be altered with respect to the molecular weight of the polyol. For example, a lower amount of a monosaccharide (e.g., mannitol) is added, compared to a disaccharide (such as trehalose). In some embodiments, the polyol which is used in the formulation as a tonicity agent is mannitol.
[0237] A detergent or surfactant may also be added to the formulation. Exemplary detergents include nonionic detergents such as polysorbates (e.g., polysorbates 20, 80 etc.) or poloxamers (e.g., poloxamer 188). The amount of detergent added is such that it reduces aggregation of the formulated antibody and / or minimizes the formation of particulates in the formulation and / or reduces adsorption. In some embodiments, the formulation may include a surfactant which is a polysorbate. In some embodiments, the formulation may contain the detergent polysorbate 80 or Tween 80. Tween 80 is a term used to describe polyoxyethylene (20) sorbitanmonooleate (see Fiedler, Lexikon der Hilfsstoffe, Editio Cantor Verlag Aulendorf, 4th edi., 1996).Attorney Docket No.: C1818.70005WO00
[0238] In embodiments, an antibody or antigen-binding fragment or antibody-drug conjugate product of the present disclosure is formulated as a liquid formulation. In some embodiments, the liquid formulation is prepared in combination with a sugar at stabilizing levels. In some embodiments, the liquid formulation is prepared in an aqueous carrier. In some embodiments, a stabilizer is added in an amount no greater than that which may result in a viscosity undesirable or unsuitable for intravenous administration. In some embodiments, the sugar is disaccharides, e.g., sucrose. In some embodiments, the liquid formulation may also include one or more of a buffering agent, a surfactant, and a preservative.
[0239] In some embodiments, the pH of the liquid formulation is set by addition of a pharmaceutically acceptable acid and / or base. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the base is sodium hydroxide.
[0240] The aqueous carrier herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation. Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (e.g., phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
[0241] A preservative may be optionally added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.
[0242] The antibody or antigen-binding fragment or antibody-drug conjugate disclosed herein may be lyophilized to produce a lyophilized formulation including the proteins and a lyoprotectant. The lyoprotectant may be sugar, e.g., disaccharides. In some embodiments, the lyoprotectant is sucrose or maltose. The lyophilized formulation may also include one or more of a buffering agent, a surfactant, a bulking agent, and / or a preservative.
[0243] The amount of sucrose or maltose useful for stabilization of the lyophilized drug product may be in a weight ratio of at least 1:2 protein to sucrose or maltose. In some embodiments, the protein to sucrose or maltose weight ratio is from 1:2 to 1:5. In some embodiments, the pH of the formulation, prior to lyophilization, is set by addition of a pharmaceutically acceptable acid and / or base. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable base is sodium hydroxide.Methods of TreatmentAttorney Docket No.: C1818.70005WO00
[0244] Described herein, in certain embodiments, are methods of treating a subject in need thereof, the method comprising a step of administering to the subject an effective amount of an antibody or antigen-binding fragment, antibody-drug conjugate or a pharmaceutical composition as disclosed herein.Subjects
[0245] In certain embodiments, the subject is a mammal, such as a primate. In some embodiments, the subject is human.
[0246] The subject may be suffering from, exhibits at least one symptom of, is diagnosed with, and / or is identified as at risk of cancer.Routes of administration
[0247] In certain embodiments, the step of administering comprises systemic administration. In certain embodiments, systemic administration comprises parenteral administration, e.g., intravenous administration, intraarterial administration, intraperitoneal administration, subcutaneous administration, or intradermal administration. In some embodiments, systemic administration comprises enteric administration, e.g., trans-gastroenteric administration or oral administration.
[0248] In some embodiments, the step of administering comprises intravenous administration. In some embodiments, the step of administering comprises subcutaneous administration.Outcomes
[0249] In many embodiments, methods disclosed herein result in a measurable improvement in the subject, e.g., in amelioration or resolution of symptoms. For example, such improvement may include an improvement in a clinical score or a score from a survey or questionnaire associated with, or suitable for assessing the disease being treated.Attorney Docket No.: C1818.70005WO00EXAMPLESExample 1: In silico mutagenesis of anti-PD-Ll antibody
[0250] Antibodies targeting PD-L1 were generated in silico with the purpose of improving internalization and cytotoxic potency as an ADC. Briefly, a crystal structure of a PD-L1 Reference Antibody Fab in complex with PD-L1 was analyzed to identify proximal amino acids which were contained within CDRs and located within 4.5 A of the PD-L1 epitope, as these are likely involved in binding. Subsequently, point mutants at each of these proximal amino acids were generated to achieve a diversity of amino acid side chain properties.
[0251] Characteristic sequences of the PD-L1 Reference Antibody are shown below:
[0252] VH:QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGI IP IFGKAHYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS(SEQ ID NO: 134)
[0253] VL:EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLI YDASNRATGIPARF SGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK(SEQ ID NO: 151)
[0254] These point mutants were expressed as full-length IgGl antibodies with Fc L234A / L235A (LALA) mutations. Briefly, the coding sequences for the heavy chain and light chain of the antibody were generated by DNA synthesis and PCR, then subsequently subcloned into plasmids for protein expression in a mammalian cell system. The gene sequences in the expression vectors were confirmed by DNA sequencing. Antibodies were then purified by a two-step affinity chromatography (Protein A) and size-exclusion chromatography process.Example 2: Determination of antibody affinity to PD-L1
[0255] Binding affinity (KD) of antibodies to human and cynomolgus monkey PD-L1 was determined through surface plasmon resonance (SPR) using a BIACORE™ 8K SPR system (Cytiva). Series S Sensor Protein G (Cytiva) chips used to determine the binding kinetic rate and affinity constants at 25°C and in a running buffer of HBS-P+ (10 mM HEPES pH 7.4, 300 mM NaCl, 3 mM EDTA and 0.05% v / v Surfactant P20). Anti-PD-Ll mAb constructs (diluted to 1 pg / mL) were captured onto flow cell 2 (active) for 60 sec at a flow rate of 10 uL / min. Recombinant human and cynomolgus monkey PD-L1 was prepared at multiple concentrations ranging from 0 - 50 nM and injected over flow cell 1 (reference) and flow cell 2 (active) for 180 sec at a flow rate of 50 pL / min. Samples were injected in a multi-cycle manner over freshlyAttorney Docket No.: C1818.70005WO00captured mAb, by regenerating the capture surfaces with injection of 10 mM glycine, pH 1.5 for 30 sec at a flow rate of 30 pL / min. A 1:1 kinetic binding model was utilized to determine the apparent association (ka) and dissociation rate constants (kd). Their ratio provides the apparent equilibrium dissociation constant or affinity constant (KD = kd / ka).
[0256] Results for the point mutant variant are shown in Tables 3 A (human PD-L1) and 3B (cynomolgus monkey PD-L1), demonstrating that affinity was meaningfully altered as compared to the PD-L1 Reference Antibody.Table 3AAntibody Hu PD-L1 ka(1 / Ms) Hu PD-L1 kd (1 / s) Hu PD-L1 KD(nM) PD-L1 ReferenceAntibody 4.70 x 1062.11 x 10-30.457.25E+06 2.68E-03 0.37 3.20E+06 2.97E-03 0.93Average: 0.58 Clone 1103 4.87 x 1063.53 x 10-27.253.23E+06 4.22E-02 13.1 3.35E+06 4.03E-02 12.0Average: 10.78Table 3BAntibody Cy PD-L1 ka(1 / Ms) Cy PD-L1 kd (1 / s) Cy PD-L1 KD(nM) PD-L1 ReferenceAntibody 3.19 x 1064.01 x 10-212.6 Clone 1103 2.06 x 1061.00 x 10-148.7Example 3: Determination of antibody internalization by pH-sensitive dye
[0257] Internalization of antibodies on human PD-L1 -expressing cell lines was determined using a pH-sensitive dye-antibody conjugate coupled with fluorescent live imaging. Given that the endosomal-lysosomal pathway, which leads to degradation and payload delivery of ADCs, becomes progressively more acidic, a pH-sensitive dye which has higher fluorescent intensity at lower pH provides a measurement of payload delivery potential.Attorney Docket No.: C1818.70005WO00
[0258] Karpas-299 cells (which express PD-L1 endogenously) were cultured in RPMI-1640 in 10% FBS. Cells were plated into 96-well plates which were pre-coated with poly-D-lysine and allowed to attach for 1-2 hours. Anti-PD-Ll antibodies were mixed with the INCUCYTE Human Fabfluor-pH Antibody Labeling reagent (Sartorius) at a molar ratio of 1:3 in media and incubated for 15 mins at 37°C, 5% CO2, protected from light. The Fabfluor-labelled antibodies were then added to the cell plates and incubated at 37°C, 5% CO2 for 24 hours in an INCUCYTE Live-Cell Analysis System (Sartorius), which imaged the cell plates every hour. Integrated fluorescent intensity was normalized to cell confluence by phase contrast imaging, and the area under the curve (AUC) of normalized integrated fluorescent intensity over time was determined in subsequent data analysis. This AUC was further normalized to account for plate-to-plate variability using an established anti-PD-Ll control antibody with internalization activity.
[0259] Results for the point mutant variant are shown in Table 4, demonstrating that internalization was significantly improved over the PD-L1 Reference Antibody.Table 4Normalized InternalizationAntibody AUCPD-L1 ReferenceAntibody 0.51Clone 1103 1.47Example 4: Conjugation of cytotoxic payloads and in vitro cytotoxicity against PD-L1-expressing cancer cell lines
[0260] In order to measure the cytotoxicity of the anti-PD-Ll antibodies as ADCs, antibodies were conjugated to cytotoxic payload-linker molecules to generate ADCs. The methods involved in the conjugation are well known in the art, where the antibodies are reduced via TCEP, payload-linkers are conjugated to the reduced interchain sulfhydryl residues through a maleimide group in the linker, and the resulting ADCs are purified. In one iteration, ADCs were generated through conjugation to mc-vc-PAB-MMAE (hereafter referred to as anti-PD-Ll MMAE ADCs), achieving an average drug-antibody ratio of 4. In one iteration, ADCs were generated through conjugation to mc-GGFG (SEQ ID NO: 143)-Dxd (hereafter referred to as anti-PD-Ll Dxd ADCs), achieving a homogeneous drug-antibody ratio of 8.Attorney Docket No.: C1818.70005WO00
[0261] These ADCs were then tested for cytotoxicity against PD-L1 -expressing cancer cell lines in vitro. Karpas-299 and EBC-1 cells (which express endogenous PD-L1) were seeded into tissue-culture plates and allowed to incubate overnight at 37°C, 5% CO2. EBC-1 cells were additionally stimulated with 250 ng / mL of IFN-y during this overnight incubation step. Cells were then treated with various concentrations of anti-PD-Ll ADCs and incubated at 37°C, 5% CO₂ for 96 hours (EBC-1 cells treated with anti-PD-Ll MMAE ADCs) or 144 hours (Karpas-299 cells treated with anti-PD-Ll Dxd ADCs). CellCounting-Lite 2.0 luminescent cell viability reagent was then added and allowed to incubate at room temperature for 10 min while shaking. Luminescent signal was measured using a PHERAstar FSX (BMG) microplate reader and data analyzed in GraphPad Prism 10. X50 (also referred to as absolute IC50) values were determined as the concentration of ADC required to inhibit 50% of cell viability of untreated control cells.
[0262] Results for the point mutant variant are shown in Table 5, demonstrating that cytotoxic potency for an ADC using the point mutant variant was significantly improved over that of an ADC using the PD-L1 Reference Antibody.Table 5Karpas 299 Cells treated with EBC-1 Cells treated with Dxd ADC MMAE ADC Antibody X50 (nM) X50 (nM)PD-L1 Reference Antibody 14.57 77.65 Clone 1103 0.24 2.29
[0263] Without wishing to be bound by theory, a reduction in binding affinity may relate to increased cytotoxicity.Example 5: In vivo efficacy of anti-PD-Ll ADCs
[0264] To further assess the potency of anti-PD-Ll ADCs, a first in vivo cell line-derived xenograft model that expresses PD-L1 in mice was used. Karpas 299 cells were implanted subcutaneously in the dorsal flank of female SCID mice at 7-8 weeks of age. Mice with tumor volume reaching an average of 101 mm3were enrolled in treatment groups (8 mice per group). Anti-PD-Ll MMAE or Anti-PD-Ll Dxd ADCs were dosed with a single treatment of 1 mg / kg intravenously to mice bearing tumors with an average volume of 101 mm3. Tumor volumes were measured twice using calipers and analyzed to quantify tumor growth inhibition. PercentAttorney Docket No.: C1818.70005WO00tumor growth inhibition measured on Day 7, Day 14, and Day 18 for anti-PD-Ll MMAE ADC treatment groups is shown in Table 6 and percent tumor growth inhibition measured on Day 9, Day 13, and Day 20 for anti-PD-Ll Dxd ADC treatment groups is shown in Table 7.Table 6Table 7
[0265] To further assess the potency of anti-PD-Ll ADCs, a second in vivo cell line-derived xenograft model that expresses PD-L1 in mice was used. The PD-L1 expressing lung carcinoma cell line, EBC-1, were implanted subcutaneously in the dorsal flank of female SCID mice at 7-8 weeks of age. Mice with tumor volume reaching an average volume of 147 mm3were enrolled in treatment groups (8 mice per group). Anti-PD-Ll MMAE ADCs were dosed as a single treatment of 3 mg / kg intravenously in mice bearing tumors with an average volume of 147 mm3. Anti-PD-Ll Dxd ADCs were dosed as a single treatment of 10 mg / kg intravenously in mice bearing tumors with an average volume of 147 mm3. Tumor volumes were measured twice weekly using calipers and analyzed to quantify tumor growth inhibition. Percent tumor growth inhibition measured on Day 10, Day 14, and Day 17 for Anti-PD-Ll MMAE ADC treatment groups is shown in Table 8, and percent tumor growth inhibition measured on Day 7, Day 11, Day 14, and Day 25 for anti-PD-Ll Dxd ADC treatment groups is shown in Table 9.Table 8Attorney Docket No.: C1818.70005WO00Table 9Example 6: Pharmacokinetic study of anti-PD-Ll ADCs in non-human primates
[0266] In vivo pharmacokinetic (PK) studies were performed on anti-PD-Ll Dxd ADCs. Studies were performed using naïve male cynomolgus monkeys, and ADCs were administered by intravenous (IV) injection. The animals weighed approximately 2 to 5 kg at transfer (n=4 per group). Animals were administered anti-PD-Ll Dxd ADCs by IV bolus injection on Day 0, and serum samples were taken at days 1, 2, 3, 7, 10, 14, 18, 21, and 28. Quantification of total antibody was used to evaluate the half-life of the ADC. The half-life of the anti-PD-Ll Dxd ADC that comprises clone 1103 was determined to be 4.7 days (which was approximately 1.5 days longer than a comparator anti-PD-Ll Dxd ADC).OTHER EMBODIMENTS
[0267] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the features set forth herein.
Claims
Attorney Docket No.: C1818.70005WO00WHAT IS CLAIMED IS:
1. A PD-L1 -binding antibody or antigen-binding fragment thereof comprising(a) an immunoglobulin heavy chain variable domain (VH) comprising complementarity-determining (CDR) regions CDR-H1, CDR-H2, and CDR- H3and(b) an immunoglobulin light chain variable region (VL) comprising CDRs CDR- Ll, CDR-L2, and CDR-L3,wherein(i) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 118, 119, and 120, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 121, DAS, and SEQ ID NO: 122, respectively;(ii) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 123, 124, and 125, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences SEQ ID NO: 126, 127, and 128, respectively; or(iii) the CDR-H1, CDR-H2, and CDR-H3 comprise the amino acid sequences of SEQ ID NOs: 129, 130, and 131, respectively, and the CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences SEQ ID NO: 132, DAS, and SEQ ID NO: 133, respectively.
2. The PD-L1 -binding antibody or antigen-binding fragment of claim 1, wherein the VH comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 134 and the VL comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 135.
3. The PD-Ll-binding antibody or antigen-binding fragment of claim 1 or 2, further comprising an Fc polypeptide.
4. The PD-Ll-binding antibody or antigen-binding fragment of claim 3, wherein the Fc polypeptide is an IgG polypeptide.Attorney Docket No.: C1818.70005WO005. The PD-L1 -binding antibody or antigen-binding fragment of claim 4, wherein the IgG is selected from the group consisting of IgGl, IgG2, IgG3, and IgG4.
6. An antibody-drug conjugate represented by Ab-Lp-Dq; wherein Ab comprises the PD- Ll-binding antibody or antigen-binding fragment thereof of any one of claims 1-5, L is a linker, D is a drug moiety, p is 1 to 10, and q is 1 to 10.
7. The antibody-drug conjugate of claim 6, wherein p and q are equal.
8. The antibody-drug conjugate of claim 7, wherein p and q are 8.
9. The antibody-drug conjugate of any one of claims 6-8, wherein D is selected from the group consisting of: maytansinoid, auristatin, anthracycline, calicheamicin, tubulysin, duocarmycin, a topoisomerase inhibitor, a radioisotope, liposome comprising a toxic payload, protein toxin, taxane, indilino-benzodiazepine pseudodimer, and pyrrolobenzodiazepine.
10. The antibody-drug conjugate of claim 9, wherein D is represented by:
11. The antibody-drug conjugate of any one of claims 6-10, wherein L is represented by the following formula:-L1-L2-Lp-NH-(CH2)n1-Ld-,whereinn1represents an integer of 0 to 6,L1represents -(Succinimid-3-yl-N)-(CH2)n2-C(=O)- wherein n2represents an integer of 2 to 8,Attorney Docket No.: C1818.70005WO00L2represents -NH-(CH2-CH2-O)n5-CH2-CH2-C(=O) or a single bond, wherein n5represents an integer of 1 to 6,Lprepresents a GGFG (SEQ ID NO: 143) tetrapeptide,-NH- (CH2)n1-Ld- is selected from the group consisting of -NH-(CH2)3- C(=O)-, -NH-CH2-O-CH2-C(=O)-, and -NH-(CH2)2-O-CH2-C(=O)-, and -(Succinimid-3-yl-N)- has a structure represented by:[Formula 2],12. The antibody-drug conjugate of claim 11, wherein the Lp-Dqcomprises an L-D having a structure represented by:[Formula 3].
13. The antibody-drug conjugate of claim 9, wherein D has a structure represented by:Attorney Docket No.: C1818.70005WO00[Formula 4]14. The antibody-drug conjugate of claim 13, wherein the Lp-Dqcomprises an L-D having a structure represented by:[Formula 5].
15. An antibody-drug conjugate comprising the following Formula:Attorney Docket No.: C1818.70005WO00wherein Ab is a PD-L1 -binding antibody or antigen-binding fragment thereof comprising:a heavy chain having the amino acid sequence of SEQ ID NO: 138;a light chain having the amino acid sequence of SEQ ID NO: 139;wherein g represents an average drug antibody ratio (DAR); andg is 8.
16. A pharmaceutical composition comprising an effective amount of the antibody-drug conjugate of any one of claims 6-15, and a pharmaceutically acceptable carrier.
17. A method of treating cancer in a mammalian subject in need thereof, the method comprising a step of administering to the mammalian subject the pharmaceutical composition of claim 16.
18. The method of claim 17, wherein the subject is human.
19. The method of any one of claims 17-18, wherein the step of administering comprises systemic administration.
20. The method of claim 19, wherein the systemic administration comprises intravenous administration.
